<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="hi" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">hi</book-part-id>
      <title-group>
        <title>Familial Hyperinsulinism</title>
        <alt-title alt-title-type="alt-title">Synonyms: FHI, Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Glaser</surname>
            <given-names>Benjamin</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Endocrinology and Metabolism<break/>Hadassah-Hebrew University Medical Center<break/>Jerusalem, Israel</aff>
          <email>ben.glaser@mail.huji.ac.il</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2003-08-19" date-type="created">
          <day>19</day>
          <month>8</month>
          <year>2003</year>
        </date>
        <date iso-8601-date="2013-01-24" date-type="updated">
          <day>24</day>
          <month>1</month>
          <year>2013</year>
        </date>
        <date iso-8601-date="2010-06-15" date-type="revised">
          <day>15</day>
          <month>6</month>
          <year>2010</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="hyperchol" document-type="chapter">Familial Hypercholesterolemia</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="lpl" document-type="chapter">Familial Lipoprotein Lipase Deficiency</related-object>
      <abstract id="hi.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Familial hyperinsulinism (referred to as FHI in this <italic toggle="yes">GeneReview</italic>) is characterized by hypoglycemia that ranges from severe neonatal-onset, difficult-to-manage disease to childhood-onset disease with mild symptoms and difficult-to-diagnose hypoglycemia. Neonatal-onset disease manifests within hours to two days after birth. Childhood-onset disease manifests during the first months or years of life. In the newborn period, presenting symptoms may be nonspecific, including seizures, hypotonia, poor feeding, and apnea. In severe cases, serum glucose concentrations are typically extremely low and thus easily recognized, whereas in milder cases, variable and mild hypoglycemia may make the diagnosis more difficult. Even within the same family, disease manifestations can range from mild to severe.</p>
          <p>Individuals with autosomal recessive familial hyperinsulinism, caused by pathogenic variants in either <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic> (FHI-K<sub>ATP</sub>), tend to be large for gestational age and usually present with severe refractory hypoglycemia in the first 48 hours of life; affected infants usually respond only partially to diet or medical management (i.e., diazoxide therapy) and thus may require pancreatic resection.</p>
          <p>Individuals with autosomal dominant FHI-K<sub>ATP</sub> tend to be appropriate for gestational age at birth, to present at approximately age one year (range: 2 days - 30 years), and to respond to diet and diazoxide therapy. Exceptions to both of these generalities have been reported.</p>
          <p>FHI-GCK, caused by pathogenic variants in <italic toggle="yes">GCK</italic>, may be much milder than FHI-K<sub>ATP</sub>; however, some persons have severe, diazoxide-unresponsive hypoglycemia.</p>
          <p>FHI-HADH, caused by pathogenic variants in <italic toggle="yes">HADH</italic>, tends to be relatively mild, although severe cases have been reported.</p>
          <p>Individuals with FHI-HNF4A, caused by pathogenic variants in <italic toggle="yes">HNF4A</italic>, are typically born large for gestational age and have mild features that respond to diazoxide treatment.</p>
          <p>FHI-UCP2, caused by pathgoenic variants in <italic toggle="yes">UCP2</italic>, is a rare cause of diazoxide-responsive FH1.</p>
          <p>Hyperammonemia/hyperinsulinism (HA/HI) is associated with mild-to-moderate hyperammonemia and with relatively mild, late-onset hypoglycemia; most but not all affected individuals have pathogenic variants in <italic toggle="yes">GLUD1</italic>.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Approximately 45% of affected individuals have pathogenic variants in either <italic toggle="yes">ABCC8</italic>, which encodes the protein SUR1, or <italic toggle="yes">KCNJ11</italic>, which encodes the protein Kir6.2. In the Ashkenazi Jewish population, two <italic toggle="yes">ABCC8</italic> founder variants are responsible for approximately 97% of FHI. Other <italic toggle="yes">ABCC8</italic> founder variants are present in the Finnish population (p.Val187Asp and p.Asp1506Lys). Pathogenic variants in <italic toggle="yes">GLUD1</italic> and <italic toggle="yes">HNF4A</italic> each account for approximately 5% of individuals with FHI. Activating pathogenic variants in <italic toggle="yes">GCK</italic> or inactivating pathogenic variants in <italic toggle="yes">HADH</italic> occur in fewer than 1% of individuals with FHI. Pathogenic variants in <italic toggle="yes">UCP2</italic> have been reported in only two families to date. Approximately 40% of individuals with FHI do not have an identifiable pathogenic variant in any of the genes known to be associated with FHI.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> At initial diagnosis, hypoglycemia is corrected with intravenous glucose to normalize plasma glucose concentration and prevent brain damage. Long-term medical management includes the use of diazoxide, somatostatin analogs, nifedipine, glucagon, recombinant IGF-I, glucocorticoids, human growth hormone, dietary intervention, or combinations of these therapies. In individuals in whom aggressive medical management fails to maintain plasma glucose concentration within safe limits, or in whom such therapy cannot be safely maintained over time, pancreatic resection is considered.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Aggressive treatment to prevent hypoglycemia helps avoid irreversible brain damage.</p>
          <p><italic toggle="yes">Surveillance:</italic> Monitoring of plasma glucose concentrations, especially during intercurrent illness.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Prolonged fasting of any sort.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> If the family-specific pathogenic variant(s) are known, early identification of at-risk relatives by molecular genetic testing ensures initiation of treatment before hypoglycemia occurs.</p>
          <p><italic toggle="yes">Pregnancy management</italic>: Affected pregnant women who have diabetes due to prior pancreatectomy should receive the same treatment as any pregnant woman who has pre-existing diabetes from any cause.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>FHI-K<sub>ATP</sub>, caused by pathogenic variants in either <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic>, is most commonly inherited in an autosomal recessive manner and less commonly in an autosomal dominant manner, although <italic toggle="yes">de novo</italic> pathogenic variants have been reported. FHI-GCK, caused by pathogenic variants in <italic toggle="yes">GCK</italic>, and HA/HI, caused by pathogenic variants in <italic toggle="yes">GLUD1</italic>, are inherited in an autosomal dominant manner; <italic toggle="yes">de novo</italic> pathogenic variants are not rare. FHI-HADH, caused by pathogenic variants in <italic toggle="yes">HADH</italic>, is inherited in an autosomal recessive manner. The focal form of FHI (pancreatic adenomatous hyperplasia that involves a limited region of the pancreas), caused by biallelic mutation of <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic>, is inherited in an autosomal dominant manner, but only manifests when the pathogenic variant occurs on the paternally derived allele and a somatic event results in the loss of the maternal allele in a beta cell precursor. Risk to sibs of a proband depends on the underlying genetic mechanism. Carrier testing for relatives at risk for the autosomal recessive forms of FHI and prenatal diagnosis for pregnancies at increased risk for the diffuse form of FHI (involvement of beta cells throughout the pancreas) are possible if the family-specific pathogenic variant(s) are known. Prenatal or preimplantation genetic diagnosis for focal FHI is not possible, as a somatic pathogenic variant in the pancreas is required for clinical disease.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="hi.Diagnosis">
        <title>Diagnosis</title>
        <sec id="hi.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Familial hyperinsulinism (FHI) is defined as hypoglycemia in the newborn or infant, associated with inappropriately elevated serum concentration of insulin and metabolic evidence of increased insulin action. The latter may include inappropriately low serum ketone bodies, increased glucose response to glucagon administration, and a glucose requirement to prevent hypoglycemia that is greater than the obligate glucose needs of the appropriate age group.</p>
        </sec>
        <sec id="hi.Testing">
          <title>Testing</title>
          <p>For most individuals, the definitive diagnosis of FHI can be made rapidly if the appropriate blood and urine samples are obtained during an episode of spontaneous hypoglycemia [<xref ref-type="bibr" rid="hi.REF.glaser.1999.55">Glaser et al 1999</xref>, <xref ref-type="bibr" rid="hi.REF.kapoor.2009.101">Kapoor et al 2009</xref>] (see <xref ref-type="table" rid="hi.T.diagnostic_tests_for_documentation">Table 1</xref>):</p>
          <list list-type="order">
            <list-item>
              <label>1</label>
              <p>At time of hypoglycemia, either spontaneous or during monitored fasting (glucose &#x0003c;40 mg/dL), obtain three to six blood samples for measurements.</p>
            </list-item>
            <list-item>
              <label>2</label>
              <p>Obtain urine samples for measurements.</p>
            </list-item>
            <list-item>
              <label>3</label>
              <p>Perform glucagon stimulation test. A glycemic response of greater than 30 mg/dL following injection of 0.03 mg/kg glucagon excludes a primary hepatic or metabolic defect.</p>
            </list-item>
            <list-item>
              <label>4</label>
              <p>Calculate glucose requirement. A requirement of greater than 15 mg/kg/min is highly suggestive of HI. Normal requirements:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Neonate: 5-8 mg/kg/min</p>
                </list-item>
                <list-item>
                  <p>Older infant or child: 3-5 mg/kg/min</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Note: Provocative tests with insulin secretagogues may be dangerous and are contraindicated.</p>
          <table-wrap id="hi.T.diagnostic_tests_for_documentation" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Diagnostic Tests for Documentation of HI</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1"/>
                  <th id="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Factor</th>
                  <th id="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Expected Result in HI</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_1" rowspan="11" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Blood samples</bold>
                  </td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Insulin</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Inappropriately elevated</td>
                </tr>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">C-peptide</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Elevated</td>
                </tr>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Free fatty acids</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Inappropriately low</td>
                </tr>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">&#x003b2;-hydroxybutyrate</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Inappropriately low</td>
                </tr>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Acetoacetate</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Inappropriately low</td>
                </tr>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Lactic acid</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                </tr>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Carnitine</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                </tr>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Growth hormone</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Elevated due to hypoglycemia</td>
                </tr>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Cortisol</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Elevated due to hypoglycemia</td>
                </tr>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">T<sub>4</sub>, T<sub>3</sub>, TSH</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                </tr>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ammonia</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Elevated in HI/HA syndrome only</td>
                </tr>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Urine samples</bold>
                  </td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Ketone bodies (at time of hypoglycemia)</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Negative</td>
                </tr>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Reducing substances</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Negative</td>
                </tr>
                <tr>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">C-peptide</td>
                  <td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Elevated</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Reprinted from <xref ref-type="bibr" rid="hi.REF.glaser.1999.55">Glaser et al [1999]</xref> with permission from Elsevier</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Severe disease.</bold> In a newborn or young infant with severe disease that appears shortly after birth, the diagnosis of FHI can be based on documentation of inappropriately elevated plasma insulin concentration (&#x0003e;14.4 pmol/L [2 &#x003bc;U/mL]) in the presence of symptomatic hypoglycemia (plasma glucose concentration &#x0003c;2.7 mmol/L [50 mg/dL]).</p>
          <p>Note: (1) "Inappropriately elevated insulin levels" are difficult to define, largely because of marked differences in specificity and sensitivity of commercial insulin assays. The concentrations mentioned here and in the literature must not be taken as hard cut-offs. (2) Pathologic hypoglycemia levels are not defined in any age group, particularly newborns.</p>
          <p><bold>Mild disease.</bold> In some cases, particularly those with milder disease appearing after the first few days or weeks of life, fasting plasma insulin concentrations may fluctuate greatly, and the presence of pathologically elevated insulin concentrations may be difficult to demonstrate convincingly. In these individuals, the following surrogate measurements of insulin action can be useful:</p>
          <list list-type="bullet">
            <list-item>
              <p>Inappropriate hypoketonemia (free fatty acid concentration &#x0003c;1.5 mmol/L)</p>
            </list-item>
            <list-item>
              <p>Exaggerated glycemic response to glucagon (&#x0003e;1.7 mmol/L [30 mg/dL] at a time of hypoglycemia)</p>
            </list-item>
            <list-item>
              <p>A markedly elevated glucose requirement to prevent hypoglycemia (i.e., exogenous glucose requirements that may exceed 15-20 mg/kg/min [normal: 5-8 mg/kg/min])</p>
            </list-item>
          </list>
          <p><bold>Hyperammonemia/hyperinsulinism syndrome.</bold> Mildly to moderately elevated serum concentration of ammonia (serum ammonia levels 1.5-4.0 times the upper limit of normal for specific assay) suggests the presence of the hyperammonemia/hyperinsulinism syndrome.</p>
          <p><bold>Hyperinsulinism caused by pathogenic variants in <italic toggle="yes">HADH</italic>.</bold> Elevated urinary 3-hydroxyglutaric acid excretion suggests this diagnosis [<xref ref-type="bibr" rid="hi.REF.clayton.2001.457">Clayton et al 2001</xref>, <xref ref-type="bibr" rid="hi.REF.molven.2004.221">Molven et al 2004</xref>], but a normal plasma acylcarnitine profile and urine organic acid analysis does not exclude this diagnosis. Individuals with this form of disease typically develop severe hypoglycemia after leucine administration [<xref ref-type="bibr" rid="hi.REF.stanley.2011.465">Stanley 2011</xref>].</p>
          <p><bold>Histology.</bold> Pancreatic beta cells (comprising &#x0003c;2% of all pancreatic cells) synthesize, store, and secrete insulin. Beta cells are located within the islets of Langerhans. Two major pancreatic histologic types (&#x02018;diffuse&#x02019; and &#x02018;focal&#x02019;) are recognized in familial hyperinsulinism. A third histologic form (&#x02018;atypical&#x02019; or &#x02018;mosaic&#x02019;) has recently been described, although the genetic etiology of this form of FHI has not yet been discovered [<xref ref-type="bibr" rid="hi.REF.sempoux.2011.3785">Sempoux et al 2011</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Diffuse</bold> involvement of beta cells throughout the pancreas. Seen in approximately 60%-70% of individuals, diffuse disease is characterized by essentially normal neonatal pancreatic architecture. All beta cells are affected and many have large nuclei, abundant cytoplasm and histologic evidence of increased metabolic activity.</p>
            </list-item>
            <list-item>
              <p><bold>Focal</bold> pancreatic adenomatous hyperplasia. Seen in approximately 30%-40% of individuals, focal changes involve a limited region of the pancreas, with the remainder of the tissue being both histologically and functionally normal. A focal lesion is the confluence of apparently normal islets. Focal lesions typically are not macroscopically visible; they differ from true adenomas, which can be identified on gross inspection of the pancreas. Beta cells outside the focal lesion have small nuclei and sparse cytoplasm-histologic evidence that they are suppressed and not actively producing and secreting insulin.</p>
            </list-item>
            <list-item>
              <p><bold>Mosaic</bold> involvement of the pancreatic islets. Pancreatic histology reveals the coexistence of two types of islet: large islets with cytoplasm-rich beta cells and occasional enlarged nuclei alongside shrunken islets with beta cells exhibiting little cytoplasm and small nuclei. Large islets are mostly confined to a few lobules suggesting that removal of these particular lobules by partial pancreatectomy could result in a cure [<xref ref-type="bibr" rid="hi.REF.sempoux.2011.3785">Sempoux et al 2011</xref>]. The genetic etiology of this form of FHI is not known.</p>
            </list-item>
          </list>
          <p><bold>Transhepatic percutaneous pancreatic venous sampling (TPPVS)</bold> was used in the past to differentiate between diffuse and focal FHI; however, it has largely been supplanted by F-Dopa PET, which is safer and easier. TPPVS is discussed here because it is still mentioned in the medical literature.</p>
          <p>TPPVS must be performed by an experienced radiologist, supported by a pediatric endocrinologist. A catheter is placed through the liver into the portal vein. Insulin concentration is determined from blood samples taken from veins draining different regions of the pancreas. Simultaneous peripheral venous or arterial insulin concentrations are obtained. Prior to and throughout the test, the individual's serum glucose concentrations must be maintained at less than 50 mg/dL to prevent insulin secretion from normal beta cells:</p>
          <list list-type="bullet">
            <list-item>
              <p>A positive gradient across all regions of the pancreas is diagnostic of diffuse disease.</p>
            </list-item>
            <list-item>
              <p>A positive gradient only in veins draining a discrete region of the pancreas is diagnostic of a focal lesion within that region.</p>
            </list-item>
          </list>
          <p>Note: The test can be interpreted accurately only if samples are taken from the small veins directly draining regions of the pancreas. Spurious results are likely if blood is sampled only from the major veins, such as the splenic, portal, and superior mesenteric veins.</p>
          <p><bold>Fluorodopa positron emission tomography (F-DOPA-PET)</bold> scanning has been used successfully for the preoperative localization of focal lesions [<xref ref-type="bibr" rid="hi.REF.otonkoski.2006.13">Otonkoski et al 2006</xref>, <xref ref-type="bibr" rid="hi.REF.mohnike.2008a.65">Mohnike et al 2008a</xref>]. DOPA is concentrated in secretory granules, where it is transformed to dopamine by the enzyme DOPA decarboxylase. Dopamine is thus trapped within the granule until secreted. Immunohistologic studies have shown that DOPA decarboxylase is normally present in both islet and exocrine cells of the pancreas. Furthermore, zymogen granules in the ascinar cells also appear to contain dopamine. Thus, the diffuse uptake and trapping of F-DOPA that is seen throughout the entire pancreas on F-DOPA-PET may be due primarily to the exocrine tissue. While distribution of the enzyme is similar in control individuals and in affected individuals with diffuse FHI, in those with focal HI the enzyme distribution appears to be lower in the exocrine tissue, except in the immediate vicinity of the lesion. Also, beta cell expression of DOPA decarboxylase appears to be increased in the focal lesion. Thus, most affected individuals with focal HI demonstrate focal uptake of the tracer, whereas individuals with diffuse disease have diffuse tracer uptake [<xref ref-type="bibr" rid="hi.REF.de_lonlay.2006.933">de Lonlay et al 2006</xref>]. In approximately 70%-80% of histologically proven focal HI, the uptake will be sufficiently concentrated in the region of the lesion to allow detection and localization on preoperative scan. This test does not require the technical expertise needed to perform TPPVS, and more importantly, it does not require that the affected individual be maintained with mild hypoglycemia prior to and during the test; however, it does require access to 18F-DOPA (which is not readily available in all centers) and extensive experience in interpreting the scans.</p>
          <sec id="hi.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Genes.</bold> There are seven genes in which mutation is known to cause FHI (see <xref ref-type="table" rid="hi.T.summary_of_molecular_genetic_testin">Table 2</xref> and <xref ref-type="sec" rid="hi.Molecular_Genetics">Molecular Genetics</xref>):</p>
            <list list-type="bullet">
              <list-item>
                <p><bold><italic toggle="yes">ABCC8</italic></bold> encodes the ATP-binding cassette transporter subfamily C member 8.</p>
              </list-item>
              <list-item>
                <p><bold><italic toggle="yes">KCNJ11</italic></bold> encodes the ATP-sensitive inward rectifier potassium channel 11.</p>
              </list-item>
              <list-item>
                <p><bold><italic toggle="yes">GLUD1</italic></bold> encodes the mitochondrial glutamate dehydrogenase 1.</p>
              </list-item>
              <list-item>
                <p><bold><italic toggle="yes">HNF4A</italic></bold> encodes for hepatocyte nuclear factor 4-alpha.</p>
              </list-item>
              <list-item>
                <p><bold><italic toggle="yes">GCK</italic></bold> encodes the enzyme glucokinase.</p>
              </list-item>
              <list-item>
                <p><bold><italic toggle="yes">HADH</italic></bold> (previously known as <italic toggle="yes">HADHSC</italic> or <italic toggle="yes">SCHAD</italic>) encodes the mitochondrial hydroxylacyl-coenzyme A.</p>
              </list-item>
              <list-item>
                <p><bold><italic toggle="yes">UCP2</italic></bold> encodes the mitochondrial uncoupling protein 2.</p>
              </list-item>
            </list>
            <p><bold>Evidence for locus heterogeneity.</bold> In approximately 40% of affected individuals, no pathogenic variants can be identified in <italic toggle="yes">ABCC8</italic>, <italic toggle="yes">KCNJ11</italic>, <italic toggle="yes">GLUD1</italic>, <italic toggle="yes">HNF4A</italic>, <italic toggle="yes">GCK</italic>, or <italic toggle="yes">HADH</italic>. It is not known if these individuals have regulatory or intronic variants in these genes, major deletions/rearrangements that may have been missed by sequence analysis, or pathogenic variants in another as-yet unidentified gene(s). Recently, individuals with FHI-associated pathogenic variants in <italic toggle="yes">UCP2</italic> were reported, although they appear to be exceedingly rare [<xref ref-type="bibr" rid="hi.REF.gonz_lezbarroso.2008.e3850">Gonz&#x000e1;lez-Barroso et al 2008</xref>]. Comprehensive screening of <italic toggle="yes">UCP2</italic> in individuals with FHI without known pathogenic variants has not been reported to date.</p>
            <p>See also <xref ref-type="sec" rid="hi.Differential_Diagnosis">Differential Diagnosis</xref> for disorders distinct from FHI that present with neonatal hypoglycemia.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <table-wrap id="hi.T.summary_of_molecular_genetic_testin" position="anchor" orientation="portrait">
              <label>Table 2. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Familial Hyperinsulinism</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of FHI Attributed to Mutation of This Gene&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variants Detected&#x000a0;<sup>3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">ABCC8</italic>
                    </td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_2" rowspan="4" valign="middle" align="left" colspan="1">45%&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">Targeted analysis for pathogenic variants</td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="table" rid="hi.T.selected_abcc8_pathogenic_variants">p.Phe1387del</xref>, <xref ref-type="table" rid="hi.T.selected_abcc8_pathogenic_variants">c.3989-9G&#x0003e;A</xref>&#x000a0;<sup>5</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" colspan="1" align="left" scope="col" rowspan="1"><xref ref-type="table" rid="hi.T.selected_abcc8_pathogenic_variants">p.Val187Asp</xref>, <xref ref-type="table" rid="hi.T.selected_abcc8_pathogenic_variants">p.Glu1506Lys</xref>&#x000a0;<sup>6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">(Multi)exon deletions&#x000a0;<sup>8</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">KCNJ11</italic>
                    </td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">5%&#x000a0;<sup>10</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown, none reported&#x000a0;<sup>11</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">GLUD1</italic>
                    </td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">5%&#x000a0;<sup>12</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis of select exons</td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Exons 6,7,10,11,12&#x000a0;<sup>13</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">HNF4A</italic>
                    </td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">5%&#x000a0;<sup>14</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown, none reported&#x000a0;<sup>11</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">GCK</italic>
                    </td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">&#x0003c;1%&#x000a0;<sup>15</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">None reported&#x000a0;<sup>16</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">HADH</italic>
                    </td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">&#x0003c;1%&#x000a0;<sup>17</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">(Multi)exon deletions <sup>18</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">UCP2</italic>
                    </td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;&#x0003c;1%&#x000a0;<sup>19</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_hi.T.summary_of_molecular_genetic_testin_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="hi.TF.2.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="hi" object-id="hi.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="hi.TF.2.2">
                  <label>2. </label>
                  <p>Percentages are different in populations with known founder variants, such as the Ashkenazi Jewish and Finnish populations.</p>
                </fn>
                <fn id="hi.TF.2.3">
                  <label>3. </label>
                  <p>See <xref ref-type="sec" rid="hi.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="hi.TF.2.4">
                  <label>4. </label>
                  <p>Approximately 40%-45% of affected individuals have pathogenic variants in <italic toggle="yes">ABCC8</italic> (previously known as <italic toggle="yes">SUR1</italic>) [<xref ref-type="bibr" rid="hi.REF.nestorowicz.1998.1119">Nestorowicz et al 1998</xref>, <xref ref-type="bibr" rid="hi.REF.aguilarbryan.1999.101">Aguilar-Bryan &#x00026; Bryan 1999</xref>, <xref ref-type="bibr" rid="hi.REF.meissner.1999.351">Meissner et al 1999</xref>, <xref ref-type="bibr" rid="hi.REF.fournet.2003.30">Fournet &#x00026; Junien 2003</xref>, <xref ref-type="bibr" rid="hi.REF.tornovsky.2004.6224">Tornovsky et al 2004</xref>].</p>
                </fn>
                <fn id="hi.TF.2.5">
                  <label>5. </label>
                  <p>In the Ashkenazi Jewish population, two <italic toggle="yes">ABCC8</italic> founder variants are responsible for approximately 97% of FHI [<xref ref-type="bibr" rid="hi.REF.glaser.2011.891">Glaser et al 2011</xref>].</p>
                </fn>
                <fn id="hi.TF.2.6">
                  <label>6. </label>
                  <p>Two founder variants have been identified in Finnish population [<xref ref-type="bibr" rid="hi.REF.otonkoski.1999.408">Otonkoski et al 1999</xref>, <xref ref-type="bibr" rid="hi.REF.huopio.2000.897">Huopio et al 2000</xref>].</p>
                </fn>
                <fn id="hi.TF.2.7">
                  <label>7. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="hi.TF.2.8">
                  <label>8. </label>
                  <p>A few exon or multiexon deletions have been reported in <italic toggle="yes">ABCC8</italic> (see <related-object source-id="gene" document-id="hi" object-id="hi.molgen.TA">Table A</related-object>).</p>
                </fn>
                <fn id="hi.TF.2.9">
                  <label>9. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="hi.TF.2.10">
                  <label>10. </label>
                  <p>Approximately 5% of individuals have pathogenic variants in <italic toggle="yes">KCNJ11</italic> (The proteins encoded by <italic toggle="yes">ABCC8</italic> and <italic toggle="yes">KCNJ11</italic> make up the beta cell K<sub>ATP</sub> channel, which regulates insulin secretion.) [<xref ref-type="bibr" rid="hi.REF.thomas.1996.1809">Thomas et al 1996</xref>, <xref ref-type="bibr" rid="hi.REF.nestorowicz.1997.1743">Nestorowicz et al 1997</xref>, <xref ref-type="bibr" rid="hi.REF.tornovsky.2004.6224">Tornovsky et al 2004</xref>].</p>
                </fn>
                <fn id="hi.TF.2.11">
                  <label>11. </label>
                  <p>No deletions or duplications involving <italic toggle="yes">KCNJ11</italic> or <italic toggle="yes">HNF4A</italic> have been reported to cause hyperinsulinism.</p>
                </fn>
                <fn id="hi.TF.2.12">
                  <label>12. </label>
                  <p>Approximately 5% of individuals have activating pathogenic variants in <italic toggle="yes">GLUD1</italic>, the gene encoding the enzyme glutamine dehydrogenase (GDH) [<xref ref-type="bibr" rid="hi.REF.stanley.2000.667">Stanley et al 2000</xref>, <xref ref-type="bibr" rid="hi.REF.bahibuisson.2008.945">Bahi-Buisson et al 2008</xref>].</p>
                </fn>
                <fn id="hi.TF.2.13">
                  <label>13. </label>
                  <p>Exons sequenced may vary by laboratory.</p>
                </fn>
                <fn id="hi.TF.2.14">
                  <label>14. </label>
                  <p>Approximately 5% of patients with diazoxide-responsive FHI have <italic toggle="yes">HNF4A</italic> pathogenic variants [<xref ref-type="bibr" rid="hi.REF.flanagan.2010.987">Flanagan et al 2010</xref>].</p>
                </fn>
                <fn id="hi.TF.2.15">
                  <label>15. </label>
                  <p>Rarely, individuals have activating pathogenic variants in <italic toggle="yes">GCK</italic>, the gene encoding the enzyme glucokinase [<xref ref-type="bibr" rid="hi.REF.glaser.1998.226">Glaser et al 1998</xref>, <xref ref-type="bibr" rid="hi.REF.christesen.2002.1240">Christesen et al 2002</xref>, <xref ref-type="bibr" rid="hi.REF.cuestamu_oz.2004.2164">Cuesta-Mu&#x000f1;oz et al 2004</xref>, <xref ref-type="bibr" rid="hi.REF.sayed.2009.1419">Sayed et al 2009</xref>].</p>
                </fn>
                <fn id="hi.TF.2.16">
                  <label>16. </label>
                  <p>No deletions or duplications involving GCK have been reported to cause hyperinsulinism.</p>
                </fn>
                <fn id="hi.TF.2.17">
                  <label>17. </label>
                  <p>Rarely, individuals have recessive, inactivating pathogenic variants in <italic toggle="yes">HADH</italic>, the gene encoding the enzyme L-3-hydroxyacyl-coenzyme A dehydrogenase, short chain [<xref ref-type="bibr" rid="hi.REF.clayton.2001.457">Clayton et al 2001</xref>, <xref ref-type="bibr" rid="hi.REF.molven.2004.221">Molven et al 2004</xref>, <xref ref-type="bibr" rid="hi.REF.di_candia.2009.1019">Di Candia et al 2009</xref>].</p>
                </fn>
                <fn id="hi.TF.2.18">
                  <label>18. </label>
                  <p>Rare large deletions including exon 1 have been reported [<xref ref-type="bibr" rid="hi.REF.flanagan.2011.e498">Flanagan et al 2011</xref>].</p>
                </fn>
                <fn id="hi.TF.2.19">
                  <label>19. </label>
                  <p>Two families with dominant pathogenic variants in <italic toggle="yes">UCP2</italic>, the gene encoding mitochondrial uncoupling protein 2, have been reported [<xref ref-type="bibr" rid="hi.REF.gonz_lezbarroso.2008.e3850">Gonz&#x000e1;lez-Barroso et al 2008</xref>].</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="hi.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> The testing strategy should be tailored to the individual.</p>
          <p>
            <bold>Targeted analysis for pathogenic variants</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>In certain genetically homogeneous populations, the presence of founder variants may allow targeted genetic testing in the initial diagnosis. These tests are easy, relatively inexpensive, and rapid, and can greatly aid in diagnosis and treatment in such cases:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Individuals of Ashkenazi Jewish descent should be tested for the two <italic toggle="yes">ABCC8</italic> pathogenic variants commonly found in individuals with FHI in this ethnic group (<xref ref-type="table" rid="hi.T.summary_of_molecular_genetic_testin">Table 2</xref>).</p>
                </list-item>
                <list-item>
                  <p>Individuals of Finnish heritage should be tested for the foundervariants in <italic toggle="yes">ABCC8</italic> identified in this population (<xref ref-type="table" rid="hi.T.summary_of_molecular_genetic_testin">Table 2</xref>).</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Individuals with elevated serum ammonia should first be tested for pathogenic variants in <italic toggle="yes">GLUD1</italic>. Sequencing of exons 6, 7, 10, 11, and 12 identifies virtually all pathogenic variants in this gene, although it is possible that causative variants occur in other exons as well.</p>
            </list-item>
          </list>
          <p><bold>Comprehensive molecular genetic testing</bold> may focus on selected genes or on a multi-gene panel.</p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals with neonatal onset of severe disease that is not responsive to diazoxide therapy should undergo molecular genetic testing of <italic toggle="yes">ABCC8</italic> and <italic toggle="yes">KCNJ11</italic> first. Unless a specific pathogenic variant has been previously identified in the individual's family or ethnic group, sequencing of the entire coding sequence and regulatory region is required. If no pathogenic variant is identified, sequence analysis of <italic toggle="yes">GCK</italic> should be pursued, as persons with pathogenic variants in this gene can present with severe disease that is phenotypically indistinguishable from FHI-K<sub>ATP</sub> [<xref ref-type="bibr" rid="hi.REF.cuestamu_oz.2004.2164">Cuesta-Mu&#x000f1;oz et al 2004</xref>, <xref ref-type="bibr" rid="hi.REF.kassem.2010.1348">Kassem et al 2010</xref>].</p>
            </list-item>
            <list-item>
              <p>In individuals with elevated urine 3-hydroxyglutaric acid, full gene sequencing followed by deletion/duplication analysis of <italic toggle="yes">HADH</italic> should be considered. Note: The finding of normal urinary 3-hydoxyglutaric acid and a normal plasma acylcarnitine profile does not exclude the diagnosis of FHI-HADH.</p>
            </list-item>
            <list-item>
              <p>Some individuals who have relatively mild diazoxide-sensitive hypoglycemia may have pathogenic variants in <italic toggle="yes">HNF4A, HADH,</italic>
<italic toggle="yes">GCK, KCNJ11, ABCC8,</italic> or (rarely) <italic toggle="yes">UCP2</italic>; in others, no pathogenic variant can be identified in any gene tested.</p>
            </list-item>
            <list-item>
              <p>Tests of multi-gene panels is another strategy for comprehensive molecular diagnosis of a proband suspected of having familial hyperinsulinemia. The genes included and the methods used in multi-gene panels vary by laboratory and over time; a panel may not include a specific gene of interest.</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for relatives at risk of being carriers of autosomal recessive forms of FHI</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for these autosomal recessive disorders and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variant(s) in the family.</p>
        </sec>
      </sec>
      <sec id="hi.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="hi.Clinical_Description">
          <title>Clinical Description</title>
          <p>Familial hyperinsulinism (FHI) is characterized by hypoglycemia, which ranges from severe neonatal-onset difficult-to-manage disease to childhood-onset disease with mild symptoms and difficult-to-diagnose hypoglycemia. Adult-onset diffuse hyperinsulinism has been reported, although it is not known whether the genetic pathogenesis of this entity is the same as for the childhood-onset disease [<xref ref-type="bibr" rid="hi.REF.service.1999.1582">Service et al 1999</xref>, <xref ref-type="bibr" rid="hi.REF.won.2006.566">Won et al 2006</xref>]. Neonatal-onset disease manifests within hours to two days after birth; presenting symptoms may be nonspecific, including seizures, hypotonia, poor feeding, and apnea. "Late-onset" disease manifests during the first months or years of life. Even within the same family, disease manifestations can range from mild to severe and clinical presentation can range from immediately after birth to late in childhood.</p>
          <p>
            <bold>Subgroups of diffuse FHI</bold>
          </p>
          <p><bold>FHI-K<sub>ATP</sub></bold> (<bold>FHI-K<sub>ATP</sub>-related FHI,</bold> caused by mutation of either <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic>) is the most common form and can be further subgrouped into autosomal recessive (more common) and autosomal dominant (rarer).</p>
          <p>The <italic toggle="yes">ABCC8</italic> pathogenic variant c.3989-9G&#x0003e;A, frequently found in individuals with autosomal recessive FHI in the Ashkenazi Jewish population, is associated with disease of variable severity. Neonates with autosomal recessive FHI-K<sub>ATP</sub> tend to be large for gestational age (mean birth weight: 4.6 &#x000b1; 0.7 kg) [<xref ref-type="bibr" rid="hi.REF.thornton.1998.9">Thornton et al 1998</xref>]; they usually present with severe refractory hypoglycemia in the first 48 hours of life and respond only partially to diet or medical management (i.e., diazoxide therapy), and thus may require pancreatic resection [<xref ref-type="bibr" rid="hi.REF.de_lonlay.2002.37">de Lonlay et al 2002</xref>]. Persons with FHI-K<sub>ATP</sub> who present with severe, neonatal hypoglycemia but who respond sufficiently well to medical treatment to avoid pancreatectomy, improve over time, first becoming more responsive to medical interventions and eventually entering clinical remission after months to years of treatment. Some may develop diabetes later in life [<xref ref-type="bibr" rid="hi.REF.mazoraronovitch.2007.491">Mazor-Aronovitch et al 2007</xref>].</p>
          <p>Individuals with autosomal dominant FHI-K<sub>ATP</sub> appear to have a much milder disease that is responsive to diazoxide therapy [<xref ref-type="bibr" rid="hi.REF.huopio.2000.897">Huopio et al 2000</xref>, <xref ref-type="bibr" rid="hi.REF.pinney.2008.2877">Pinney et al 2008</xref>, <xref ref-type="bibr" rid="hi.REF.macmullen.2011.1797">Macmullen et al 2011</xref>, <xref ref-type="bibr" rid="hi.REF.o_al.2011.1019">O&#x000e7;al et al 2011</xref>].</p>
          <p>Approximately 40% of individuals with FHI-K<sub>ATP</sub> have the focal form of the disease. Clinically, these individuals present like those with autosomal recessive FHI-K<sub>ATP</sub>; however, the genetic and therapeutic aspects of this subtype of disease are distinctly different (see Management, <xref ref-type="sec" rid="hi.Treatment_of_Manifestations">Treatment of Manifestations</xref>, <bold>Surgical management</bold> and <bold>Genetic studies</bold>).</p>
          <p><bold>FHI-GCK</bold> (<bold>FHI-GCK-related FHI</bold>, caused by pathogenic variants in <italic toggle="yes">GCK</italic>). To date, only a few families, each with a different dominant pathogenic variant, have been reported [<xref ref-type="bibr" rid="hi.REF.glaser.1998.226">Glaser et al 1998</xref>, <xref ref-type="bibr" rid="hi.REF.christesen.2002.1240">Christesen et al 2002</xref>, <xref ref-type="bibr" rid="hi.REF.cuestamu_oz.2004.2164">Cuesta-Mu&#x000f1;oz et al 2004</xref>, <xref ref-type="bibr" rid="hi.REF.sayed.2009.1419">Sayed et al 2009</xref>, <xref ref-type="bibr" rid="hi.REF.kassem.2010.1348">Kassem et al 2010</xref>]. The clinical presentation of FHI-GCK varies from mild to severe. Insulin secretion in response to elevation and suppression of glucose levels is qualitatively normal, but the glucose set-point at which insulin secretion is turned off is abnormally low. Some (not all) individuals with <italic toggle="yes">GCK</italic> pathogenic variants respond well to diazoxide therapy.</p>
          <p><bold>Hyperammonemia/hyperinsulinism (HA/HI)</bold> is associated with mild-to-moderate hyperammonemia and with relatively mild hypoglycemia, usually appearing after the neonatal period. Most but not all affected individuals have pathogenic variants in <italic toggle="yes">GLUD1</italic>. Ammonia levels are not related to ambient glucose levels or to duration of fasting and appear to be benign. Hypoglycemia is typically relatively mild, becomes clinically evident after the newborn period, and may be associated with exquisite sensitivity to leucine challenge. Most individuals respond well to diazoxide therapy and only a minority require surgery to prevent recurrent hypoglycemia [<xref ref-type="bibr" rid="hi.REF.stanley.2000.667">Stanley et al 2000</xref>, <xref ref-type="bibr" rid="hi.REF.de_lonlay.2001.353">de Lonlay et al 2001</xref>, <xref ref-type="bibr" rid="hi.REF.kelly.2001.3724">Kelly et al 2001</xref>, <xref ref-type="bibr" rid="hi.REF.macmullen.2001.1782">MacMullen et al 2001</xref>, <xref ref-type="bibr" rid="hi.REF.bahibuisson.2008.945">Bahi-Buisson et al 2008</xref>].</p>
          <p><bold>FHI-HADH</bold> (<bold>FHI-HADH-related FHI,</bold> caused by mutation of <italic toggle="yes">HADH</italic>) is associated with relatively mild, diazoxide-responsive hypoglycemia as well as elevated urine 3-hydroxyglutaric acid and serum 3-hydroxybutyryl-carnitine [<xref ref-type="bibr" rid="hi.REF.clayton.2001.457">Clayton et al 2001</xref>, <xref ref-type="bibr" rid="hi.REF.molven.2004.221">Molven et al 2004</xref>, <xref ref-type="bibr" rid="hi.REF.hardy.2007.765">Hardy et al 2007</xref>]. Recently, <italic toggle="yes">HADH</italic> pathogenic variants have been identified in individuals without abnormal serum or urinary organic acid profiles [<xref ref-type="bibr" rid="hi.REF.flanagan.2011.e498">Flanagan et al 2011</xref>]. Mutated HADH fails to suppress beta-cell GLUD1 activity resulting in leucine-sensitive hypoglycemia very similar to that seen in individuals with FHI-GLUD1 [<xref ref-type="bibr" rid="hi.REF.stanley.2011.465">Stanley 2011</xref>]. Therefore, pathogenic variants in <italic toggle="yes">HADH</italic> should be sought in all individuals with diazoxide-responsive chronic hyperinsulinism (CHI), particularly those from consanguineous families and those who have leucine-induced hypoglycemia.</p>
          <p><bold>FHI-HNF4A</bold> (<bold>FHI-HNF4A-related FHI,</bold> caused by mutation of <italic toggle="yes">HNF4A</italic>) was recently reported in about 5% of diazoxide-responsive individuals with FHI. Hypoglycemia was sometimes transient, remitting after a few months; but in some cases longer-term treatment was needed. Since many of these affected individuals had <italic toggle="yes">de novo</italic> pathogenic variants, a family history of FHI or the maturity-onset diabetes of the young type 1 (MODY1) phenotype was not elicited. Therefore, it was concluded that analysis for <italic toggle="yes">HNF4A</italic> pathogenic variants should be performed in all individuals with diazoxide-responsive FHI after pathogenic variants in <italic toggle="yes">ABCC8</italic> and <italic toggle="yes">KCNJ11</italic> are excluded [<xref ref-type="bibr" rid="hi.REF.flanagan.2010.987">Flanagan et al 2010</xref>]. This finding was based on the observation that a history of transient fetal overgrowth and neonatal hypoglycemia can been elicited in some individuals with MODY1 caused by autosomal dominant pathogenic variants in <italic toggle="yes">HNF4A</italic> but not MODY3, which is caused by mutation of <italic toggle="yes">HNF1A</italic> [<xref ref-type="bibr" rid="hi.REF.pearson.2007.e118">Pearson et al 2007</xref>, <xref ref-type="bibr" rid="hi.REF.kapoor.2008.1659">Kapoor et al 2008</xref>]. The mechanism by which hyperinsulinemic hypoglycemia in the fetal and neonatal period develops into insulinopenic diabetes mellitus during adolescence and young adulthood is not yet understood.</p>
          <p><bold>FHI-UCP2</bold> (<bold>FHI-UCP2-related FHI</bold>, caused by mutation of <italic toggle="yes">UCP2</italic>) was recently discovered in two unrelated persons with diazoxide-sensitive FHI. The patients were normal weight at birth, and the disease was transient in one whereas the other had persistent disease at last follow-up (age 2 years). This patient&#x02019;s mother, who carried the same pathogenic variant, had a history of seizures during infancy, but hypoglycemia was not documented. The syndrome appears to be inherited as an autosomal dominant trait with variable penetrance.</p>
        </sec>
        <sec id="hi.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No genotype-phenotype correlations other than those described in <xref ref-type="sec" rid="hi.Clinical_Description">Clinical Description</xref> are known.</p>
        </sec>
        <sec id="hi.Penetrance">
          <title>Penetrance</title>
          <p>Autosomal recessive FHI demonstrates nearly complete penetrance. Some splice variants, particularly the <italic toggle="yes">ABCC8</italic> pathogenic variant common in the Ashkenazi Jewish population, present with markedly variable clinical severity; some homozygous individuals may be asymptomatic.</p>
          <p>The focal form of FHI is inherited in an autosomal dominant manner with significantly reduced penetrance. It results from inheritance of a paternally derived <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic> pathogenic variant and a somatic event resulting in the loss of the maternal allele (loss of heterozygosity) [<xref ref-type="bibr" rid="hi.REF.ryan.1998.445">Ryan et al 1998</xref>, <xref ref-type="bibr" rid="hi.REF.verkarre.1998.1286">Verkarre et al 1998</xref>, <xref ref-type="bibr" rid="hi.REF.damaj.2008.4941">Damaj et al 2008</xref>]. The risk for disease development to a fetus carrying a recessive <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic> pathogenic variant inherited from its father has been estimated at 1:270 [<xref ref-type="bibr" rid="hi.REF.glaser.2011.891">Glaser et al 2011</xref>].</p>
          <p>A retrospective review of individuals diagnosed with MODY1 caused by pathogenic variants in <italic toggle="yes">HNF4A</italic> revealed an increased mean birth weight and increased incidence of hypoglycemia in the neonatal period [<xref ref-type="bibr" rid="hi.REF.pearson.2007.e118">Pearson et al 2007</xref>]. However, significant macrosomia or clinical hypoglycemia were not common, suggesting that in individuals with <italic toggle="yes">HNF4A</italic> pathogenic variants, the FHI phenotype has a low penetrance, whereas in the MODY phenotype, penetrance appears to be quite high.</p>
        </sec>
        <sec id="hi.Anticipation">
          <title>Anticipation</title>
          <p>Children with autosomal dominant FHI frequently have more severe hypoglycemia than their genetically affected parents; it is not known if this is the result of anticipation or an ascertainment artifact.</p>
        </sec>
        <sec id="hi.Nomenclature">
          <title>Nomenclature</title>
          <p>Since its initial description, FHI has been given a number of descriptive names. The most common is "nesidioblastosis." Derived from the Greek "nesidion" meaning islet, "blastos" meaning germ cell, and "osis" meaning tumor, this term refers to the apparent increase in the number of beta cells and to the apparent proliferation and disorganization of the islets of Langerhans, with pleomorphic, poorly formed islets and a large number of isolated beta cells apparently budding off of pancreatic ducts. More rigorous histologic evaluation and comparison with age-matched controls revealed that these findings are not specific for the disease. However, although universally considered to be technically inaccurate, the term nesidioblastosis is still in wide use.</p>
          <p>FHI has also been called islet dysmaturation syndrome, a term derived from the observation that, like FHI beta cells, fetal beta cells respond poorly to glucose stimulation, and from the clinical observation that some individuals enter clinical remission after months or years of medical management. However, no molecular evidence exists for progressive normalization of beta-cell function over time, and thus the use of this term should be discontinued. The apparent clinical remission may be attributed to deceased beta-cell mass caused by increased apoptosis [<xref ref-type="bibr" rid="hi.REF.kassem.2000.1325">Kassem et al 2000</xref>].</p>
          <p>FHI has also been given names containing adjectives such as &#x0201c;congenital&#x0201d; and &#x0201c;persistent.&#x0201d; However, these have been opposed by some, since most cases are simplex (i.e., a single occurrence within a family), and some appear after the neonatal period and are thus not truly congenital. The descriptive name "persistent hyperinsulinemic hypoglycemia of infancy" is perhaps the most precise term, but has been rejected as being too cumbersome. Thus, the terminology most accepted today is simply "hyperinsulinism of infancy" (HI), adding descriptive terms such as familial, hyperammonemia, or the mutated gene whenever possible for individual cases.</p>
          <p>Many of the individuals previously described as having leucine-sensitive hypoglycemia may have had the HA/HI syndrome or FHI-HADH.</p>
        </sec>
        <sec id="hi.Prevalence">
          <title>Prevalence</title>
          <p>Familial hyperinsulinism has been reported in virtually all major ethnic groups. Incidence has been estimated at 1:50,000 in the European population, whereas consanguineous populations of central Finland and Saudi Arabia have disease incidence of approximately 1:2,500. The incidence in Ashkenazi Jews is estimated at 1: 7,800, about 27% of whom have focal disease [<xref ref-type="bibr" rid="hi.REF.glaser.2011.891">Glaser et al 2011</xref>].</p>
        </sec>
      </sec>
      <sec id="hi.Genetically_Related_Allelic_Disorders">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold><italic toggle="yes">ABCC8</italic> and <italic toggle="yes">KCNJ11</italic>.</bold> Sequence variants in <italic toggle="yes">ABCC8</italic> and <italic toggle="yes">KCNJ11</italic> (particularly the p.Glu23Lys polymorphism in <italic toggle="yes">KCNJ11</italic>; also known as <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000525.3">NM_000525.3</ext-link>:c.635A&#x0003e;G; p.Lys23Glu) have been associated with type 2 diabetes mellitus (DM) in some but not all studies [<xref ref-type="bibr" rid="hi.REF.hani.1998.1511">Hani et al 1998</xref>, <xref ref-type="bibr" rid="hi.REF.gloyn.2001.206">Gloyn et al 2001</xref>, <xref ref-type="bibr" rid="hi.REF.hansen.2001.1330">Hansen et al 2001</xref>, <xref ref-type="bibr" rid="hi.REF.hart.2002.3135">Hart et al 2002</xref>, <xref ref-type="bibr" rid="hi.REF.gloyn.2003.568">Gloyn et al 2003</xref>]. These findings are still controversial but a recent meta-analysis suggests that at least in some ethnic groups the <italic toggle="yes">KCNJ11</italic> p.Glu23Lys variant is associated with a significant (albeit small) increased risk for type 2 DM [<xref ref-type="bibr" rid="hi.REF.gong.2012.801">Gong et al 2012</xref>, <xref ref-type="bibr" rid="hi.REF.morris.2012.981">Morris et al 2012</xref>]. A dominant <italic toggle="yes">ABCC8</italic> pathogenic variant is associated with hyperinsulinemic hypoglycemia in the neonatal period and diabetes mellitus later in life [<xref ref-type="bibr" rid="hi.REF.glaser.2003.272">Glaser 2003</xref>, <xref ref-type="bibr" rid="hi.REF.huopio.2003.301">Huopio et al 2003</xref>].</p>
        <p>Dominant and recessive activating pathogenic variants of either <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic> can cause severe neonatal diabetes mellitus with and without associated neurologic defects. Many such individuals can be managed with oral sulfonylurea treatment and do not require insulin [<xref ref-type="bibr" rid="hi.REF.gloyn.2004.1838">Gloyn et al 2004</xref>, <xref ref-type="bibr" rid="hi.REF.zung.2004.5504">Zung et al 2004</xref>, <xref ref-type="bibr" rid="hi.REF.flanagan.2009.170">Flanagan et al 2009</xref>] (see <related-object link-type="booklink" source-id="gene" document-id="dmn" document-type="chapter">Permanent Neonatal Diabetes Mellitus</related-object>).</p>
        <p>Activating pathogenic variants in either <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic> with less severe effects on channel function have been found to cause transient neonatal diabetes mellitus (TNDM) as well as both childhood-onset diabetes mellitus and adult-onset autosomal dominantly inherited type 2 DM [<xref ref-type="bibr" rid="hi.REF.gloyn.2005.925">Gloyn et al 2005</xref>, <xref ref-type="bibr" rid="hi.REF.yorifuji.2005.3174">Yorifuji et al 2005</xref>, <xref ref-type="bibr" rid="hi.REF.flanagan.2009.170">Flanagan et al 2009</xref>]. More recently, diabetes was found to be linked to a novel <italic toggle="yes">KCNJ11</italic> pathogenic variant in a large multi-generational family with a MODY phenotype [<xref ref-type="bibr" rid="hi.REF.bonnefond.2012.e37423">Bonnefond et al 2012</xref>].</p>
        <p><bold><italic toggle="yes">GCK.</italic></bold> Heterozygosity for inactivating pathogenic variants in <italic toggle="yes">GCK</italic> is a common cause of maturity-onset diabetes of the young (MODY) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/606391">OMIM</ext-link>), a rare form of type 2 diabetes mellitus inherited in an autosomal dominant manner [<xref ref-type="bibr" rid="hi.REF.sagen.2008.442">Sagen et al 2008</xref>].</p>
        <p>Homozygosity for inactivating pathogenic variants in <italic toggle="yes">GCK</italic> results in severe, persistent neonatal diabetes mellitus [<xref ref-type="bibr" rid="hi.REF.nj_lstad.2001.1588">Nj&#x000f8;lstad et al 2001</xref>, <xref ref-type="bibr" rid="hi.REF.turkkahraman.2008.122">Turkkahraman et al 2008</xref>] (see <related-object link-type="booklink" source-id="gene" document-id="dmn" document-type="chapter">Permanent Neonatal Diabetes Mellitus</related-object>).</p>
        <p><bold><italic toggle="yes">HNF4A</italic>.</bold> The same <italic toggle="yes">HNF4A</italic> pathogenic variants that cause FHI also cause one form of maturity-onset diabetes of the young (MODY1) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/600281">OMIM</ext-link>), making FHI-HNF4A part of the MODY1 phenotype. Variants in the beta-cell promoter of <italic toggle="yes">HNF4A</italic> are associated with type 2 diabetes [<xref ref-type="bibr" rid="hi.REF.lovegregory.2004.1134">Love-Gregory et al 2004</xref>, <xref ref-type="bibr" rid="hi.REF.barroso.2008.3161">Barroso et al 2008</xref>].</p>
        <p><bold><italic toggle="yes">UCP2.</italic></bold> Genetic variants within and around <italic toggle="yes">UCP2</italic> have been associated with abdominal obesity or type 2 diabetes risk in some studies, but these results are controversial and variants in this gene have not yet been identified by unbiased genome-wide association studies [<xref ref-type="bibr" rid="hi.REF.salopuro.2009.94">Salopuro et al 2009</xref>, <xref ref-type="bibr" rid="hi.REF.dalgaard.2011">Dalgaard 2011</xref>].</p>
      </sec>
      <sec id="hi.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Familial hyperinsulinism (FHI) is the most common cause of persistent neonatal hypoglycemia and should be considered in every infant presenting with unexplained hypoglycemia. High birth weight for gestational age and elevated glucose requirement to prevent hypoglycemia strongly suggest the diagnosis of FHI. However, hyperinsulinemic hypoglycemia can be seen in disorders other than FHI. Furthermore, neonatal hypoglycemia can be caused by non-insulin mediated mechanisms, in which case plasma insulin concentrations are low and plasma glucose concentrations can be readily corrected with normal replacement doses of glucose (5-8 mg/kg/min).</p>
        <sec id="hi.NonFHI_Hyperinsulinemic_Hypoglycemia">
          <title>Non-FHI Hyperinsulinemic Hypoglycemia</title>
          <p>Hyperinsulinemic hypoglycemia may be differentiated clinically from the other causes of hypoglycemia described below by demonstrating non-suppressed plasma insulin concentrations, relative hypoketonemia, or very high glucose requirements to prevent recurrent hypoglycemia. The latter may be the first, and perhaps the most sensitive, indication of increased, unregulated insulin action.</p>
          <p><bold>Infants of diabetic mothers</bold> may present with a clinical picture identical to that of FHI; in such cases, however, the hypoglycemia is transient, resolving within days to weeks after birth.</p>
          <p><bold>Transient hyperinsulinemic hypoglycemia of infancy,</bold> not associated with maternal diabetes mellitus, is a poorly characterized entity that may be associated with perinatal stress or asphyxia or may occur without apparent precipitating factors. Individuals with transient neonatal hyperinsulinism typically respond well to diazoxide therapy.</p>
          <p><bold>Beckwith-Wiedemann syndrome.</bold> Approximately 30% of infants with <related-object link-type="booklink" source-id="gene" document-id="bws" document-type="chapter">Beckwith-Wiedemann syndrome</related-object> have hyperinsulinemic hypoglycemia, although it is typically mild and responds to medical treatment with diazoxide.</p>
          <p><bold>Exercise-induced hyperinsulinemic hypoglycemia</bold> (listed in OMIM as familial hyperinsulinemic hypoglycemia type 7) is caused by dominant pathogenic variants in <italic toggle="yes">SLC16A1</italic>. The clinical phenotype is quite different from that seen in other forms of FHI, as individuals with pathogenic variants in <italic toggle="yes">SLC16A1</italic> typically present with severe hypoglycemia occurring after anaerobic and not aerobic exercise. In the majority of cases, hypoglycemia was first diagnosed during childhood or later and not during infancy or the neonatal period. Pathogenic variants in the regulatory region of <italic toggle="yes">SLC16A1</italic> result in aberrant expression of the transporter in beta cells, allowing pyruvate and lactate to enter the beta cell and stimulate insulin secretion even in the absence of glucose [<xref ref-type="bibr" rid="hi.REF.otonkoski.2003.199">Otonkoski et al 2003</xref>, <xref ref-type="bibr" rid="hi.REF.otonkoski.2007.467">Otonkoski et al 2007</xref>].</p>
          <p><bold>Insulin receptor pathogenic variants</bold> have also been associated with hyperinsulinemic hypoglycemia and have been designated in OMIM as familial hyperinsulinemic hypoglycemia type 5. However, here too, the clinical symptoms are quite different from those seen in other forms of FHI, with affected individuals presenting with post-prandial hypoglycemia three to five hours after meals. An inactivating pathogenic variant in the gene for the insulin receptor, <italic toggle="yes">INSR</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/147670">OMIM</ext-link>), is thought to decrease insulin clearance, resulting in increased insulin/C-peptide ratio and prolonged postprandial insulin action [<xref ref-type="bibr" rid="hi.REF.h_jlund.2004.1592">H&#x000f8;jlund et al 2004</xref>]. Thus, unlike other forms of hyperinsulinemic hypoglycemia, the genetic defect is not thought to directly affect the beta cell itself.</p>
          <p><bold>Insulinoma.</bold> In children older than age one year, insulinoma must be excluded; it is rarely if ever seen before age one year. Familial insulinomas can be seen as part of <related-object link-type="booklink" source-id="gene" document-id="men1" document-type="chapter">multiple endocrine neoplasia type 1</related-object>; however, in that disorder they rarely present during infancy or early childhood. Insulinomas are true adenomas or (rarely) carcinomas, visible macroscopically and composed of beta cells only, which are arranged in nests or cords [<xref ref-type="bibr" rid="hi.REF.rahier.2000.f108">Rahier et al 2000</xref>].</p>
        </sec>
        <sec id="hi.Hypoglycemias_NOT_Associated_with_Hyp">
          <title>Hypoglycemias NOT Associated with Hyperinsulinemia</title>
          <p>To exclude these other potential causes of hypoglycemia, plasma samples for C-peptide, free fatty acids, beta-hydroxybutyrate, acetoacetate, lactic acid, carnitine, growth hormone, cortisol, and thyroid hormones should be obtained at the same time as the plasma samples to be tested for glucose and insulin concentrations. Counter-regulatory hormones in individuals with familial hyperinsulinism are usually normal; however, recurrent hypoglycemia can significantly blunt the growth hormone and cortisol response.</p>
          <list list-type="bullet">
            <list-item>
              <p>Congenital deficiency of cortisol or growth hormone may first present with hypoglycemia, although it is also typically mild and responds well to hormone replacement therapy.</p>
            </list-item>
            <list-item>
              <p>Ketotic, or substrate-deficient, hypoglycemia is rare and typically presents between ages 18 and 24 months.</p>
            </list-item>
            <list-item>
              <p>Defects in fatty-acid, glucose, and amino acid metabolism are rare, but they frequently present with hypoglycemia, and the specific diagnosis is important for appropriate treatment.</p>
            </list-item>
          </list>
          <p><bold>Defects in glucose production.</bold> The glycogen storage diseases are a class of diseases caused by mutation in any of several enzymes responsible for the generation or breakdown of glycogen, including glycogen synthase (glycogen storage disease type 0) and glucose-6-phospatase (see <related-object link-type="booklink" source-id="gene" document-id="gsd1" document-type="chapter">Glycogen Storage Disease Type I</related-object>). Since glycogen is the major source of glucose during a short fast, these diseases are characterized by fasting hypoglycemia, the severity of which depends on the specific gene mutated and the nature of the specific pathogenic variant.</p>
          <p>Similarly, mutation in any of several of the enzymes in the gluconeogenesis pathway can result in hypoglycemia. For example, fructose 1,6-diphosphatase deficiency (F1,6 DH) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/229700">OMIM</ext-link>) presents with lactic acidosis and hypoglycemia. Hypoglycemia in F1,6 DH is less severe than that caused by glucose-6-phosphatase deficiency (glycogen storage disease type Ia), occurring primarily during fasting or intercurrent illness (see <related-object link-type="booklink" source-id="gene" document-id="gsd1" document-type="chapter">Glycogen Storage Disease Type I</related-object>). Glucose response to glucagon can be normal in the postprandial period, emphasizing the importance of performing the glucagon test during fasting hypoglycemia, when glycogen stores are depleted in the absence of circulating hyperinsulinism. Treatment consists of high-carbohydrate diet, avoidance of fasting, and treatment with intravenous glucose during catabolic situations.</p>
          <p><bold>Defects in fatty acid metabolism.</bold> Fatty acid beta-oxidation is an important energy source, particularly during fasting and times of metabolic stress such as acute illness. Disorders of fatty acid oxidation, including <related-object link-type="booklink" source-id="gene" document-id="mcad" document-type="chapter">MCAD deficiency</related-object>, are rare but important causes of hypoglycemia in the infant [<xref ref-type="bibr" rid="hi.REF.lteif.1999.619">Lteif &#x00026; Schwenk 1999</xref>, <xref ref-type="bibr" rid="hi.REF.kompare.2008.140">Kompare &#x00026; Rizzo 2008</xref>]. The process of fatty acid beta-oxidation is complex and involves a cascade of enzymes, transporters, and co-factors. Disruption of this process at any level results in failure to metabolize fatty acids, leading to loss of a critical energy source and failure to produce ketone bodies. During prolonged aerobic exercise, fasting, or any intercurrent illness, fatty acid oxidation accounts for a major part of muscle oxygen consumption. In contrast, brain energy requirements are supplied primarily by glucose and secondarily by oxidation of ketone bodies.</p>
          <p>Individuals with fatty-acid oxidation disorders have both hypoglycemia and hypoketonemia and are thus particularly prone to neurologic damage. The mechanism by which these disorders cause hypoglycemia is unclear; it is thought to be the combined effect of at least two factors:</p>
          <list list-type="bullet">
            <list-item>
              <p>Increased peripheral glucose utilization resulting from the absence of fatty acids and ketone bodies as alternative energy sources may rapidly deplete glycogen stores and overtax the gluconeogenesis machinery.</p>
            </list-item>
            <list-item>
              <p>Hepatic gluconeogenesis may be further inhibited nonspecifically because of decreased energy sources needed to drive the process or specifically by inhibition of pyruvate carboxylase, the first gluconeogenic enzyme, since this enzyme requires acetyl-CoA for optimal activity.</p>
            </list-item>
          </list>
          <p>The clinical presentation of most fatty-acid oxidation disorders is similar. The diagnosis is suspected clinically when fasting hypoketotic hypoglycemia is found in the absence of hyperinsulinism. Myopathy and/or cardiomyopathy may also be prominent features. Acute symptoms are typically precipitated by fasting or by acute intercurrent illness.</p>
          <p>The diagnosis can be made by urine organic acid analysis and measurement of the concentration of plasma carnitine and acylcarnitines. Electrospray tandem mass spectrometry can be used to obtain an acylcarnitine profile, which is usually diagnostic for specific defects [<xref ref-type="bibr" rid="hi.REF.rashed.1999.183">Rashed et al 1999</xref>, <xref ref-type="bibr" rid="hi.REF.kompare.2008.140">Kompare &#x00026; Rizzo 2008</xref>].</p>
          <p><bold>Counter-regulatory hormone deficiency.</bold> Both growth hormone deficiency and cortisol deficiency result in decreased hepatic gluconeogenesis and decreased gluconeogenic substrate availability. In the adult, symptomatic hypoglycemia is rarely associated with deficiency of either or both of these hormones; however, in the neonate and small child, hypoglycemia is common, particularly if both hormones are deficient.</p>
          <p>Primary adrenal insufficiency may be the result of congenital adrenal hyperplasia (see <related-object link-type="booklink" source-id="gene" document-id="cah" document-type="chapter">21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia</related-object>) or primary adrenal hypoplasia (see <related-object link-type="booklink" source-id="gene" document-id="ahc" document-type="chapter">X-Linked Adrenal Hypoplasia</related-object> Congenita). Affected individuals typically present with ketotic hypoglycemia, suppressed plasma insulin levels, and blunted glycemic response to glucagon.</p>
          <p>Pituitary hormone deficiencies can be single or multiple and can occur either as isolated entities (e.g., PIT1, <related-object link-type="booklink" source-id="gene" document-id="prop1" document-type="chapter"><italic toggle="yes">PROP1</italic>-related combined pituitary hormone deficiency</related-object> [CPHD]) or as part of a syndrome of midline defects (e.g., septo-optic dysplasia).</p>
          <p>At initial presentation, individuals with isolated growth hormone deficiency may have low plasma concentrations of ketone bodies and may not have ketonuria. The diagnosis is made by measuring plasma growth hormone concentration and cortisol concentration during spontaneous or induced hypoglycemia. Recurrent hypoglycemia per se may secondarily blunt the cortisol response to acute hypoglycemia. Therefore, an isolated, blunted cortisol response in the face of recurrent hypoglycemia must be interpreted with caution. Another stimulatory test may be indicated to confirm the diagnosis.</p>
          <p>Treatment of hypoglycemia resulting from deficiency of GH and/or cortisol is based on immediate correction of the hypoglycemia with intravenous glucose, followed by appropriate hormone replacement.</p>
          <p><bold>Infantile seizures.</bold> In individuals with mild FHI, the diagnosis of hypoglycemia may be made after age one year, but retrospective analysis typically suggests a much earlier onset. These individuals may be misdiagnosed as having infantile seizures if plasma glucose concentrations are not determined during an attack.</p>
          <p><bold>Hyperammonemia.</bold> It is necessary to evaluate individuals with hyperammonemia/hyperinsulinism for an organic acidemia, a urea cycle defect (see <related-object link-type="booklink" source-id="gene" document-id="ucd-overview" document-type="chapter">Urea Cycle Disorders Overview</related-object>), and defects in fatty acid metabolism (see <related-object link-type="booklink" source-id="gene" document-id="mcad" document-type="chapter">MCAD Deficiency</related-object>.)</p>
        </sec>
      </sec>
      <sec id="hi.Management">
        <title>Management</title>
        <sec id="hi.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Initial treatment.</bold> Once initial diagnostic blood samples are obtained, the hypoglycemia must be corrected immediately using intravenous glucose at a dose sufficient to prevent further hypoglycemia and irreversible brain damage. The dose of glucose may be high (&#x0003e;15 mg/kg/min) and frequently requires central venous access. The definition of adequate glucose control has been the subject of discussion. Most investigators recommend maintaining all glucose levels above 3.3 mmol/L (60 mg/dL), a level that leaves a sufficient margin to prevent frequent episodes of neuroglycopenia (i.e., transient or permanent brain dysfunction caused by inadequate glucose supplies) [<xref ref-type="bibr" rid="hi.REF.burns.2008.65">Burns et al 2008</xref>, <xref ref-type="bibr" rid="hi.REF.inder.2008.440">Inder 2008</xref>].</p>
          <p><bold>Long-term medical management.</bold> The next phase of treatment, designed to decrease and stop parenteral glucose requirement, is empiric and involves a combination of medical therapies, which may include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Diazoxide, which binds to the ABCC8 subunit of the K<sub>ATP</sub> channel, increases the channel's probability of being open, resulting in membrane hyperpolarization and inhibition of insulin release. Some evidence suggests that diazoxide binding to mutated channels may correct abnormal protein folding and thus facilitate the transit of more channels to the membrane. The effective therapeutic dose varies but may be as high as 20 mg/kg/day in divided doses. A thiazide diuretic is always given along with diazoxide to prevent fluid retention, which may be severe [<xref ref-type="bibr" rid="hi.REF.hussain.2004.163">Hussain et al 2004</xref>].</p>
            </list-item>
            <list-item>
              <p>Somatostatin analogs (e.g., octreotide or lanreotide) suppress insulin secretion by binding to specific beta-cell receptors and initiating a number of intracellular signaling pathways. The clinical efficacy of these analogs may be limited by the relatively short duration of inhibition of insulin secretion after subcutaneous bolus injection (~3 hours) and by the fact that these drugs also inhibit glucagon and growth hormone secretion, thus impairing hepatic glucose production. Careful attention to dosage (typically 10/40 &#x003bc;g/kg/day for octreotide) as well as the use of continuous subcutaneous injection using a portable pump greatly enhances clinical efficacy [<xref ref-type="bibr" rid="hi.REF.glaser.1989.71">Glaser et al 1989</xref>, <xref ref-type="bibr" rid="hi.REF.hussain.2004.163">Hussain et al 2004</xref>]. Simultaneous treatment with glucagon or growth hormone may enhance efficacy.</p>
            </list-item>
            <list-item>
              <p>Nifedipine, which acts as an inhibitor of the voltage-dependent calcium channels present in the beta cell, inhibits insulin secretion by decreasing calcium influx [<xref ref-type="bibr" rid="hi.REF.hussain.2004.163">Hussain et al 2004</xref>]. In vitro, this drug effectively suppresses insulin secretion depending on the pathogenic variant; however, in vivo side effects are usually dose limiting, and the drug is only rarely clinically effective.</p>
            </list-item>
            <list-item>
              <p>Glucagon, which increases hepatic gluconeogenesis, helps prevents hypoglycemia. The drug can be used acutely to treat severe hypoglycemia, or chronically as replacement therapy to counteract suppression by somatostatin analogs [<xref ref-type="bibr" rid="hi.REF.mohnike.2008b.59">Mohnike et al 2008b</xref>].</p>
            </list-item>
            <list-item>
              <p>Recombinant IGF-I has been shown to suppress insulin secretion in individuals with FHI [<xref ref-type="bibr" rid="hi.REF.katz.1999.3117">Katz et al 1999</xref>]; however, therapeutic success has not been confirmed.</p>
            </list-item>
            <list-item>
              <p>Glucocorticoids induce resistance to endogenous insulin and correct the inadequate cortisol response sometimes seen in affected individuals. Their use in the treatment algorithm of FHI is, however, very limited.</p>
            </list-item>
            <list-item>
              <p>Growth hormone may be given in combination with somatostatin analogs in order to counteract GH suppression by the analogs.</p>
            </list-item>
            <list-item>
              <p>Novel treatment approaches, such as the use of a GLP1 receptor antagonist, have been attempted, but their therapeutic efficacy and safety have yet to be determined [<xref ref-type="bibr" rid="hi.REF.calabria.2012.2585">Calabria et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>Dietary intervention:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Frequent high-carbohydrate feedings, including formula supplemented with glucose polymer</p>
                </list-item>
                <list-item>
                  <p>Night-time continuous gastric drip containing glucose or glucose polymer</p>
                </list-item>
                <list-item>
                  <p>Feeding gastrostomy to simplify the process of continuous night-time feeding and to provide access for emergency home treatment of hypoglycemia</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Some individuals, particularly those with FHI-GLUD1, FHI-HADH, FHI-GCK, or dominant pathogenic variants in either <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic>, respond very well to medical therapy. Individuals with severe FHI-K<sub>ATP</sub> may also respond to medical therapy; however, these individuals often require aggressive medical management, including a combination of several of the above-mentioned drugs along with dietary intervention to maintain plasma glucose concentration in a clinically safe range without the use of parenteral glucose administration. This management protocol may be extremely demanding and, even if successful in the hospital setting, may not be appropriate for many families on an outpatient basis. The overall success of medical management in FHI-K<sub>ATP</sub> as reported by different groups is extremely variable [<xref ref-type="bibr" rid="hi.REF.mazoraronovitch.2009.424">Mazor-Aronovitch et al 2009</xref>]. The discrepancy may result from different pathogenic variants being common in various populations, or by differences in physician and patient expectations and willingness to invest time and effort in achieving success using medical management.</p>
          <p>If medical treatment can be safely maintained, glycemic control usually becomes easier with time, and most individuals treated medically enter clinical remission after several months or years of treatment [<xref ref-type="bibr" rid="hi.REF.mazoraronovitch.2009.424">Mazor-Aronovitch et al 2009</xref>]. It is generally accepted that those individuals who respond well to medical treatment can be treated chronically without undue risk for long-term complications. Long-term follow up of medically treated individuals shows that some eventually develop glucose intolerance, which can be effectively managed with mild dietary restrictions [<xref ref-type="bibr" rid="hi.REF.mazoraronovitch.2009.424">Mazor-Aronovitch et al 2009</xref>].</p>
          <p><bold>Surgical management.</bold> Once an individual is stabilized, a decision must be made as to the need for surgical intervention and the extent of such intervention. In some severe cases, even the most aggressive medical management fails to maintain plasma glucose concentration consistently within the safe limits (&#x0003e;60 mg/dL). In such individuals, surgery must be considered. Prior to surgical intervention, differentiation between focal and diffuse disease using one of the following techniques is important, as the surgical approach and the clinical outcome are quite different:</p>
          <p>Note: None of the techniques described is 100% accurate and more research is needed to develop tools to diagnose and localize focal FHI more accurately without the need for invasive testing.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Genetic studies,</bold> in certain circumstances, can be useful in differentiating focal from diffuse disease:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Finding two recessive pathogenic variants or a single dominant pathogenic variant is diagnostic of diffuse disease.</p>
                </list-item>
                <list-item>
                  <p>Finding a single recessive pathogenic variant on the maternal allele suggests diffuse disease; it is assumed that the other pathogenic variant on the paternal allele was missed because of technical limitations of the molecular genetic testing.</p>
                </list-item>
                <list-item>
                  <p>Finding a single recessive pathogenic variant on the paternal allele is consistent with and highly suggestive of focal disease, although it cannot be considered diagnostic, as molecular genetic testing methods could have failed to detect a pathogenic variant on the maternal allele. In such individuals, further testing diagnose and localize focal disease is indicated. Because of the large size of <italic toggle="yes">ABCC8</italic> and <italic toggle="yes">KNCJ11</italic>, complete sequencing and analysis of all variants discovered is expensive and time-consuming and may not be completed in time to aid in clinical decision making for a severely ill individual. With the incorporation of modern sequencing techniques, rapid complete sequencing of all relevant genes is becoming feasible. In contrast, for a person from an ethnic group with a known founder variant (e.g., Ashkenazi Jews), targeted analysis for pathogenic variants can provide rapid and inexpensive clinically useful information.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Transhepatic percutaneous pancreatic venous sampling (TPPVS)</bold> was the first effective method for diagnosing and localizing focal lesions, but has now been largely replaced by F-DOPA-PET scanning, which is easier and considerably safer to perform.</p>
            </list-item>
            <list-item>
              <p><bold>Intraoperative histologic evaluation of a pancreatic biopsy</bold> in very experienced hands can be used to differentiate between diffuse FHI and a normal, suppressed pancreas in an individual with a focal lesion. Since interoperative identification of the focal lesion can be very difficult or impossible, resection of the lesion is usually only possible if its location is determined preoperatively.</p>
            </list-item>
            <list-item>
              <p><bold>Acute insulin response</bold> to calcium, tolbutamide, and glucose can be used to diagnose the focal FHI [<xref ref-type="bibr" rid="hi.REF.grimberg.1999">Grimberg et al 1999</xref>, <xref ref-type="bibr" rid="hi.REF.ferry.2000.239">Ferry et al 2000</xref>, <xref ref-type="bibr" rid="hi.REF.grimberg.2001.322">Grimberg et al 2001</xref>, <xref ref-type="bibr" rid="hi.REF.huopio.2002.4502">Huopio et al 2002</xref>], while selective arterial calcium infusion may be useful in localizing the lesion [<xref ref-type="bibr" rid="hi.REF.abernethy.1998.359">Abernethy et al 1998</xref>, <xref ref-type="bibr" rid="hi.REF.stanley.2004.288">Stanley et al 2004</xref>]. The former, however, will not help to localize the lesion, and the latter is invasive and not without potentially serious side effects.</p>
            </list-item>
            <list-item>
              <p><bold>Fluoro-DOPA positron emission tomography (F-DOPA-PET)</bold> has been used successfully for the preoperative localization of focal lesions [<xref ref-type="bibr" rid="hi.REF.otonkoski.2006.13">Otonkoski et al 2006</xref>, <xref ref-type="bibr" rid="hi.REF.mohnike.2008a.65">Mohnike et al 2008a</xref>] (see <xref ref-type="sec" rid="hi.Diagnosis">Diagnosis</xref>). While the scan itself is relatively easy to perform, the radiopharmaceutical is not readily available in many centers and the scan can be difficult to interpret, requiring extensive experience to obtain reliable results.</p>
            </list-item>
          </list>
          <p>Individuals with diffuse disease require extensive (80%-95%) pancreatic resection and are at risk for persistent hypoglycemia postoperatively and/or insulin-requiring diabetes mellitus later in childhood. Individuals with focal disease can be cured by localized resection of the hyperplastic region. Although the apparent risk for postoperative diabetes appears to be very low after limited pancreatectomy, very long-term follow up is not yet available on these individuals [<xref ref-type="bibr" rid="hi.REF.beltrand.2012.198">Beltrand et al 2012</xref>]. Since focal lesions can only rarely be identified grossly at the time of surgery, perioperative diagnosis and localization of focal lesions is needed.</p>
        </sec>
        <sec id="hi.Prevention_of_Secondary_Complications">
          <title>Prevention of Secondary Complications</title>
          <p>Aggressive treatment to prevent hypoglycemia helps avoid irreversible brain damage.</p>
        </sec>
        <sec id="hi.Surveillance">
          <title>Surveillance</title>
          <p>In persons with clinically mild disease, episodes of subtle, undiagnosed hypoglycemia can cause permanent brain damage. Therefore close monitoring and vigilance is just as critical in mild cases as it is in severe cases. Furthermore, in persons with mild disease and in those with severe disease in clinical remission, severe hypoglycemia may be precipitated by intercurrent viral illness. Thus, it is imperative that parents monitor glucose concentrations closely especially during intercurrent illness, even in the absence of symptomatic hypoglycemia.</p>
        </sec>
        <sec id="hi.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Prolonged fasting of any sort should be avoided. Emergency treatment options for hypoglycemia must be available at all times in case of an unexpected hypoglycemic episode.</p>
        </sec>
        <sec id="hi.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Molecular genetic testing is appropriate in the sibs of affected individuals to identify those with the pathogenic variants known to be present in the family so that appropriate evaluation and treatment can be initiated before hypoglycemia occurs. Because of the severe neurologic consequences of delayed diagnosis and treatment, it is imperative that at-risk individuals be tested and a definitive diagnosis be made as rapidly as possible. Once the causative pathogenic variants have been identified in a proband, it is prudent to test all at-risk relatives. Depending on the findings, more extensive family investigations may be warranted. For further discussion of prenatal diagnosis, see <xref ref-type="sec" rid="hi.Prenatal_Testing_and_Preimplantation">Prenatal Testing</xref>.</p>
          <p>See <xref ref-type="sec" rid="hi.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="hi.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Affected individuals who previously underwent near-total or sub-total pancreatectomy typically have insulin-requiring diabetes by the time they become pregnant. In this case, treatment is the same as for individuals with preexisting diabetes from any cause. There is little, if any, experience with pregnancy in individuals who were treated conservatively or who underwent limited pancreatectomy for focal FHI, as these treatments are relatively new. In this situation, close monitoring of glucose to detect both recurrent hypoglycemia and hyperglycemia is warranted. If hyperglycemia is documented, treatment should be instituted as for any woman with gestational diabetes. A fetus at risk for FHI should be monitored for size and weight. Excessive fetal weight gain during the last trimester of pregnancy increases the risk of obstetric complications and of cesarean delivery. In pregnant women with a history of FHI and gestational hyperglycemia due to prior surgical treatment, the fetus should be monitored as for any case of preexisting type 1, preexisting type 2, or gestational diabetes.</p>
        </sec>
        <sec id="hi.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="hi.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="hi.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>FHI-K<sub>ATP</sub>, caused by mutation of either <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic>, is most commonly inherited in an autosomal recessive manner, and rarely in an autosomal dominant manner.</p>
          <p>FHI-GCK, FHI-GLUD1, FHI-HNF4A, and FHI-UCP2 are inherited in an autosomal dominant manner.</p>
          <p>FHI-HADH, caused by mutation of <italic toggle="yes">HADH</italic>, is inherited in an autosomal recessive manner.</p>
          <p>The focal form of FHI is caused by mutation of <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic> inherited in an autosomal dominant manner with markedly reduced penetrance.</p>
        </sec>
        <sec id="hi.Risk_to_Family_Members__Autosomal_Rec">
          <title>Risk to Family Members &#x02014; Autosomal Recessive Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes and therefore each carry one mutated allele.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The offspring of an individual with FHI are obligate heterozygotes (carriers) for a pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>The risk to offspring of being affected depends on the mutation frequency in the reproductive partner's ethnic group. In most cases, the carrier frequency appears to be approximately 1% or less; however, genetic isolates with very high mutated allele frequency have been reported. In Ashkenazi Jews, for example, the mutation carrier rate is estimated to be 1:52; the risk to the child of a proband would be approximately 1:104 or 1% [<xref ref-type="bibr" rid="hi.REF.glaser.2011.891">Glaser et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p>Offspring of a male carrier are at risk of developing focal FHI even if the mother does not have the pathogenic variant (see <xref ref-type="sec" rid="hi.Risk_to_Family_Members__Autosomal_Dom_1">Risk to Family Members &#x02013; AD Focal Form</xref>, <bold>Offspring of a proband</bold>). Recent studies in the Ashkenazi Jewish population suggest that the risk of the focal form of HI in a fetus of a male carrier of a recessive <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KNCJ11</italic> pathogenic variant is approximately 1:540. This risk is expected to be independent of the specific pathogenic variant involved [<xref ref-type="bibr" rid="hi.REF.glaser.2011.891">Glaser et al 2011</xref>].</p>
            </list-item>
          </list>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="hi.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing is possible if the pathogenic variants in the family are known.</p>
        </sec>
        <sec id="hi.Risk_to_Family_Members__Autosomal_Dom">
          <title>Risk to Family Members &#x02014; Autosomal Dominant Inheritance, Diffuse Form</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>One of the parents of an affected child may have a mutated allele, and thus be affected by FHI.</p>
            </list-item>
            <list-item>
              <p>A proband with HI may have the disorder as the result of a <italic toggle="yes">de novo</italic> gene pathogenic variant. The proportion of cases caused by <italic toggle="yes">de novo</italic> pathogenic variants is estimated at approximately 75% for HA/HI.</p>
            </list-item>
            <list-item>
              <p>Neither of the two families with FHI-GCK reported by <xref ref-type="bibr" rid="hi.REF.glaser.1998.226">Glaser et al [1998]</xref> or <xref ref-type="bibr" rid="hi.REF.christesen.2002.1240">Christesen et al [2002]</xref> were <italic toggle="yes">de novo</italic> in the proband's generation. However, <xref ref-type="bibr" rid="hi.REF.cuestamu_oz.2004.2164">Cuesta-Mu&#x000f1;oz et al [2004]</xref> reported a <italic toggle="yes">de novo</italic> activating <italic toggle="yes">GCK</italic> pathogenic variant that resulted in severe hyperinsulinemia in a female infant.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include molecular genetic testing, and, if positive, clinical testing for fasting and postprandial hypoglycemia.</p>
            </list-item>
          </list>
          <p>Note: Although most individuals diagnosed with dominant HI have a <italic toggle="yes">de novo</italic> pathogenic variant, the family history may also appear to be negative even when the pathogenic variant is inherited from a parent because of failure to recognize the disorder in the affected parent or other family members.</p>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p>
              <list list-type="bullet">
                <list-item>
                  <p>If a parent of the proband is affected or has a pathogenic variant, the risk to the sibs is 50%.</p>
                </list-item>
                <list-item>
                  <p>When the parents are clinically unaffected and do not have a pathogenic variant, the risk to the sibs of a proband appears to be negligible.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>If a pathogenic variant cannot be detected in the DNA from leukocytes of either parent, two possible explanations are germline mosaicism in a parent or <italic toggle="yes">de novo</italic> mutation in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with FHI has a 50% chance of inheriting the pathogenic variant.</p>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the status of the proband's parents. If a parent is affected, his or her family members are at risk.</p>
        </sec>
        <sec id="hi.Risk_to_Family_Members__Autosomal_Dom_1">
          <title>Risk to Family Members &#x02014; Autosomal Dominant Inheritance, Focal Form</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The fathers of individuals with focal FHI are heterozygous for an <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic> pathogenic variant and will not have hyperinsulinism.</p>
            </list-item>
            <list-item>
              <p>Although no instances of focal FHI caused by <italic toggle="yes">de novo</italic> mutation on the paternally derived <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic> allele have been reported, it remains a possibility.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Sibs of a proband with focal FHI have a 50% chance of inheriting the mutated allele from their father. However, the focal form of FHI manifests only when the pathogenic variant occurs on the paternally derived allele and a separate, independent somatic event results in the loss of the maternal allele (loss of heterozygosity).</p>
            </list-item>
            <list-item>
              <p>The risk for focal FHI in a sib of a proband has been estimated to be approximately 1:540 [<xref ref-type="bibr" rid="hi.REF.glaser.2011.891">Glaser et al 2011</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Each child of an individual with focal FHI has a 50% chance of inheriting the pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>The risk to offspring of having the diffuse form of hyperinsulinemia is related to the mutation frequency in the reproductive partner's ethnic group, as offspring will have this form of hyperinsulinemia only if they inherit a mutated allele from both parents.</p>
            </list-item>
            <list-item>
              <p>Each child of a male proband with focal FHI is also at risk of developing focal FHI. To develop FHI, the individual must inherit the pathogenic variant from the father (50% chance) and a second somatic event must occur, the latter being quite uncommon. The estimated risk for focal FHI to the offspring of a male proband with focal FHI is approximately 1:540 [<xref ref-type="bibr" rid="hi.REF.glaser.2011.891">Glaser et al 2011</xref>].</p>
            </list-item>
          </list>
          <p><bold>Other family members of a proband.</bold> The sibs of the father of a proband with focal FHI may also carry an <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic> pathogenic variant. However, the focal form of FHI manifests only when the pathogenic variant occurs on the paternally derived allele and a somatic event resulting in the loss of the maternal allele occurs (loss of heterozygosity). As for any child whose father carries a recessive <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic> pathogenic variant, the risk for focal FHI is estimated at 1:540 [<xref ref-type="bibr" rid="hi.REF.glaser.2011.891">Glaser et al 2011</xref>].</p>
        </sec>
        <sec id="hi.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="hi.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Mode of inheritance when no pathogenic variant is identified.</bold> Approximately 40% of individuals with HI do not have an identifiable pathogenic variant in any of the genes known to be associated with HI. Risk to family members in these families is not known.</p>
          <p>
            <bold>Family planning &#x02014; autosomal recessive inheritance</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or at risk of being carriers.</p>
            </list-item>
            <list-item>
              <p>Because of the relatively high prevalence of two specific <italic toggle="yes">ABCC8</italic> pathogenic variants in the Ashkenazi Jewish population, pre-conception genetic screening may be considered in this specific ethnic group. Similarly, such genetic screening may be considered in any ethnic group with a high carrier rate of known pathogenic variants.</p>
            </list-item>
          </list>
          <p>
            <bold>Family planning &#x02014; autosomal dominant inheritance</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="hi.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the pathogenic variant(s) have been identified in an affected family member, prenatal diagnosis and preimplantation genetic diagnosis for a pregnancy at increased risk for the diffuse form of FHI-K<sub>ATP</sub> (involvement of beta cells throughout the pancreas) or for a pregnancy at increased risk of inheriting pathogenic variants in <italic toggle="yes">HADH, GLUD1, HNF4A</italic>, or <italic toggle="yes">GCK</italic> are possible options. Parents who elect to continue a pregnancy in which the fetus has been determined to be affected have the advantage of initiating treatment immediately following birth, thus preventing early, severe hypoglycemia.</p>
          <p>In families of individuals with focal FHI (pancreatic adenomatous hyperplasia that involves a limited region of the pancreas), prenatal diagnosis is not possible, since even though the paternal pathogenic variant can be identified in the DNA of an at-risk fetus, no testing can identify which fetuses will also have a somatic event leading to loss of the maternal allele.</p>
        </sec>
      </sec>
      <sec id="hi.Resources">
        <title>Resources</title>
      </sec>
      <sec id="hi.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="hi.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Mutation of either <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic>, encoding (respectively) the proteins SUR1 (sulfonylurea receptor 1) and K<sub>IR</sub>6.2 (ATP-sensitive inward rectifier potassium channel 11), which are subunits of the beta cell K<sub>ATP</sub> channel, results in an altered or non-functional channel. The molecular mechanism by which this occurs depends on the specific pathogenic variant. Some pathogenic variants appear not to produce any protein, whereas others produce protein that is not incorporated into the plasma membrane. Other pathogenic variants result in channels that are expressed in the plasma membrane but that fail to respond appropriately to intracellular signals such as ATP and Mg-ADP levels. This latter type of variant often causes dominant disease. Mutation of <italic toggle="yes">GLUD1</italic> results in increased glutamate dehydrogenase enzymatic function, apparently by decreasing the inhibitory effect of GTP, a natural inhibitor of the enzyme. Mutation of <italic toggle="yes">GCK</italic> lowers the glucose threshold at which glucokinase enzyme activity is high enough to cause insulin secretion. The mechanism by which this is accomplished differs with the different pathogenic variants known to date. <italic toggle="yes">HADH</italic> encodes the protein hydroxyacyl-coenzyme A dehydrogenase, mitochondrial, which appears to have at least two seemingly independent functions:</p>
          <list list-type="bullet">
            <list-item>
              <p>Catalyzing the penultimate step in the fatty acid oxidation pathway; and</p>
            </list-item>
            <list-item>
              <p>Inhibiting the function of glutamate dehydrogenase in the beta-cell</p>
            </list-item>
          </list>
          <p>It is the latter function that is thought to be responsible for the FHI phenotype, as decreased HADH protein de-suppresses glutamate dehydrogenase, causing increased flux into the Krebs cycle and ultimately increased insulin secretion. The mechanism by which HNF4A-inactivating mutations cause hyperinsulinism has not yet been elucidated. Mutation of <italic toggle="yes">UCP2</italic> results in decreased protein expression or function which in the beta-cell results in increased ATP production, leading to membrane depolarization and ultimately to insulin secretion.</p>
          <sec id="hi.ABCC8">
            <title>
              <italic toggle="yes">ABCC8</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">ABCC8</italic> is located on chromosome 11p15.1, 4.5 kb centromeric to <italic toggle="yes">KCNJ11</italic>. <italic toggle="yes">ABCC8</italic> spans approximately 84 kb of genomic DNA and comprises 39 exons. It is expressed primarily in the pancreatic beta cell and in certain specific regions of the nervous system. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hi" object-id="hi.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic allelic variants.</bold> A large and growing number of <italic toggle="yes">ABCC8</italic> variants are known to be associated with FHI. Most have been identified in only a single family or in a single small genetic isolate. The c.3989-9G&#x0003e;A pathogenic variant was identified in several different ethnic groups; haplotype analysis suggests that this is a mutation hot spot. In the Ashkenazi Jewish population, this pathogenic variant represents approximately 86% of the disease-associated alleles, most of the others being p.Phe1387del. The c.560T&#x0003e;A pathogenic variant causes severe FHI in a specific genetic isolate in Finland [<xref ref-type="bibr" rid="hi.REF.otonkoski.1999.408">Otonkoski et al 1999</xref>].</p>
            <table-wrap id="hi.T.selected_abcc8_pathogenic_variants" position="anchor" orientation="portrait">
              <label>Table 3. </label>
              <caption>
                <p>Selected <italic toggle="yes">ABCC8</italic> Pathogenic Variants</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_hi.T.selected_abcc8_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                    <th id="hd_h_hi.T.selected_abcc8_pathogenic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_hi.T.selected_abcc8_pathogenic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_hi.T.selected_abcc8_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.560T&#x0003e;A</td>
                    <td headers="hd_h_hi.T.selected_abcc8_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Val187Asp&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_hi.T.selected_abcc8_pathogenic_variants_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/118582254">NM_000352.3</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/118582255">NP_000343.2</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.selected_abcc8_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3989-9G&#x0003e;A<break/>(3992-9G&#x0003e;A)</td>
                    <td headers="hd_h_hi.T.selected_abcc8_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.selected_abcc8_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.4160_4162delTCT</td>
                    <td headers="hd_h_hi.T.selected_abcc8_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Phe1387del</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hi.T.selected_abcc8_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.4516G&#x0003e;A</td>
                    <td headers="hd_h_hi.T.selected_abcc8_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu1506Lys&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_hi.T.selected_abcc8_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the author. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="hi.TF.3.1">
                  <label>1. </label>
                  <p>Variant designation that does not conform to current naming conventions</p>
                </fn>
                <fn id="hi.TF.3.2">
                  <label>2. </label>
                  <p>Founder variants in the Finnish population</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">ABCC8</italic> and <italic toggle="yes">KCNJ11</italic> code for the proteins SUR1 (sulfonylurea receptor 1) and K<sub>IR</sub>6.2 (ATP-sensitive inward rectifier potassium channel 11), two components of the beta-cell K<sub>ATP</sub> channel. This channel determines the resting membrane potential, which is maintained at the necessary voltage to keep voltage-dependent calcium channels closed in a cell that does not secrete. When glucose enters the cell and is metabolized, there is an increase in the ATP/ADP ratio. K<sub>ATP</sub> channels close and the membrane depolarizes. Subsequently, voltage-gated calcium channels open, initiating the insulin secretory cascade. Thus, the K<sub>ATP</sub> channel functions as a link between the metabolic state of the cell and the electrical activity of the membrane, resulting in the stimulation or inhibition of insulin release.</p>
            <p><bold>Abnormal gene product.</bold> Inactivating pathogenic variants in either <italic toggle="yes">ABCC8</italic> or <italic toggle="yes">KCNJ11</italic> result in non-functional or dysfunctional K<sub>ATP</sub> channels. In either case, channels fail to open, and thus the cell membrane is depolarized even in the absence of an elevated intracellular ATP/ADP ratio. This results in opening of the voltage-gated calcium channels and initiation of the insulin secretion cascade, even in the absence of glucose or other metabolic stimulus. Activating pathogenic variants in either gene result in channels that fail to close despite increased ATP/ADP ratio. As a result, beta-cell membranes fail to depolarize in the presence of elevated glucose levels resulting in one form of neonatal diabetes (see <related-object link-type="booklink" source-id="gene" document-id="dmn" document-type="chapter">Permanent Neonatal Diabetes Mellitus</related-object>).</p>
          </sec>
          <sec id="hi.KCNJ11">
            <title>
              <italic toggle="yes">KCNJ11</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">KCNJ11</italic> is located on chromosome 11p15.1, 4.5 kb telomeric to <italic toggle="yes">ABCC8</italic>. The gene spans approximately 3.4 kb of genomic DNA and comprises a single exon. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hi" object-id="hi.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic allelic variants.</bold> A large number of inactivating <italic toggle="yes">KCNJ11</italic> pathogenic variants have been identified, most in only a single family or in a single small genetic isolate (for more information, see <related-object source-id="gene" document-id="hi" object-id="hi.molgen.TA">Table A</related-object>).</p>
            <p><bold>Normal gene product.</bold> See <xref ref-type="sec" rid="hi.ABCC8"><italic toggle="yes">ABCC8</italic>.</xref></p>
            <p><bold>Abnormal gene product.</bold> See <xref ref-type="sec" rid="hi.ABCC8"><italic toggle="yes">ABCC8</italic></xref>.</p>
          </sec>
          <sec id="hi.GLUD1">
            <title>
              <italic toggle="yes">GLUD1</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">GLUD1</italic> spans just over 44 kb of genomic DNA and is made up of 13 exons. The gene product is expressed in the mitochondrial matrix in all tissues. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hi" object-id="hi.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic allelic variants.</bold> All <italic toggle="yes">GLUD1</italic> pathogenic variants identified to date are located in exons 6, 7, 10, 11, and 12 of the gene and all appear to function by reducing glutamate dehydrogenase sensitivity to allosteric inhibition by GTP (for more information, see <related-object source-id="gene" document-id="hi" object-id="hi.molgen.TA">Table A</related-object>).</p>
            <p><bold>Normal gene product.</bold> Glutamate dehydrogenase catalyzes the conversion of glutamate to alpha-ketoglutarate, a reaction that can proceed in either direction.</p>
            <p><bold>Abnormal gene product.</bold> Glutamate dehydrogenase pathogenic variants result in increased enzymatic activity. The mechanism by which this results in unregulated insulin secretion is still controversial and may relate either to increased direct mitochondrial signaling to the distal insulin secretory apparatus [<xref ref-type="bibr" rid="hi.REF.maechler.1999.685">Maechler &#x00026; Wollheim 1999</xref>] or to increase in glutamate conversion to alpha-ketoglutarate, which enters the Krebs cycle and results in glucose-independent increase in intracellular ATP/ADP ratio [<xref ref-type="bibr" rid="hi.REF.stanley.2000.667">Stanley et al 2000</xref>].</p>
          </sec>
          <sec id="hi.GCK">
            <title>
              <italic toggle="yes">GCK</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">GCK</italic> spans just over 45 kb of genomic DNA and comprises ten exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hi" object-id="hi.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic allelic variants.</bold>
<italic toggle="yes">GCK</italic> pathogenic variants have been reported (for more information, see <related-object source-id="gene" document-id="hi" object-id="hi.molgen.TA">Table A</related-object>).</p>
            <p><bold>Normal gene product.</bold> Glucokinase is the rate-limiting step of beta-cell glucose metabolism. Thus, it is effectively the beta-cell glucose sensor, linking changes in glucose levels with changes in intracellular ATP/ADP ratio [<xref ref-type="bibr" rid="hi.REF.matschinsky.1998.307">Matschinsky et al 1998</xref>]. The gene product is expressed primarily in the liver and the pancreatic beta cell but also in specific regions of the hypothalamus. Hepatic and beta-cell expression is regulated independently by tissue-specific promoters.</p>
            <p><bold>Abnormal gene product.</bold> Pathogenic variants with increased and decreased catalytic activity have been described. Those with decreased activity are associated with maturity-onset diabetes of the young (MODY) and severe neonatal diabetes, whereas activating pathogenic variants are associated with FHI.</p>
          </sec>
          <sec id="hi.HADH">
            <title>
              <italic toggle="yes">HADH</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">HADH</italic> spans approximately 45 kb of genomic DNA and comprises 12 exons. The gene is expressed in most tissues of the body. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hi" object-id="hi.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic allelic variants.</bold> Recessive inactivating pathogenic variants have been identified in a small number of individuals with hyperinsulinemic hypoglycemia (for more information, see <related-object source-id="gene" document-id="hi" object-id="hi.molgen.TA">Table A</related-object>).</p>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">HADH</italic> codes for the enzyme 3-hydroxyacyl-CoA dehydrogenase (also known as short-chain hydroxyacyl-CoA dehydrogenase), which catalyzes the reversible dehydrogenation of 3-hydroxyacyl-CoAs to their corresponding 3-ketoacyl-CoAs with concomitant reduction of NAD to NADH and exerts its highest activity toward 3-hydroxydecanoyl-CoA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/601609">OMIM</ext-link>). Recent studies have shown that this enzyme also acts as inhibitor of GLUD1 activity in the beta-cell.</p>
            <p><bold>Abnormal gene product.</bold> Recessive pathogenic variants result in decreased enzyme expression or function [<xref ref-type="bibr" rid="hi.REF.clayton.2001.457">Clayton et al 2001</xref>, <xref ref-type="bibr" rid="hi.REF.eaton.2003.1137">Eaton et al 2003</xref>, <xref ref-type="bibr" rid="hi.REF.molven.2004.221">Molven et al 2004</xref>, <xref ref-type="bibr" rid="hi.REF.hardy.2007.765">Hardy et al 2007</xref>]. Recent data suggest that the HADH gene product suppresses GLUD1 activity in the beta-cell. Thus, inactivating pathogenic variants result in increased GLUD1 activity, which increases insulin secretion through the same mechanism described above for FHI-GLUD1. This function is thought not to be important in the liver, thus explaining the absence of hyperammonemia in patients with <italic toggle="yes">HADH</italic>-related hyperinsulinemic hypoglycemia [<xref ref-type="bibr" rid="hi.REF.stanley.2011.465">Stanley 2011</xref>].</p>
          </sec>
          <sec id="hi.HNF4A">
            <title>
              <italic toggle="yes">HNF4A</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">HNF4A</italic> spans approximately 76 kb of genomic DNA and comprises ten exons. The gene is expressed primarily in the liver and the beta-cells under the control of two separate tissue-specific promoters. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hi" object-id="hi.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic allelic variants.</bold> A large number of inactivating pathogenic variants have been identified throughout the gene that cause the monogenic diabetes syndrome, maturity-onset diabetes of the young type 1 (MODY1, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/125850">OMIM</ext-link>). Persons with these pathogenic variants can present with FHI in the neonatal period.</p>
            <p><bold>Normal gene product.</bold> HNF4A is a transcription factor, regulating the expression of a large number of genes in the liver and beta-cell.</p>
            <p><bold>Abnormal gene product.</bold> Pathogenic variants identified in patients with MODY1 and FHI-HNF4A result in decreased function of the transcription factor, thus affecting critical gene expression. The precise mechanism by which this results in transient hyperinsulinemic hypoglycemia, followed by permanent hypoinsulinemic diabetes is not clear.</p>
          </sec>
          <sec id="hi.UCP2">
            <title>
              <italic toggle="yes">UCP2</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">UCP2</italic> spans approximately 8.6 kb of genomic DNA and comprises eight exons. The gene is ubiquitously expressed. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hi" object-id="hi.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic allelic variants.</bold> At the present time, only two families with dominant pathogenic loss-of-function variants in this gene have been reported.</p>
            <p><bold>Normal gene product.</bold> UCP2 is a mitochondrial protein that provides a pathway for dissipating the mitochondrial membrane proton gradient without coupling to other mitochondrial processes. As a result, excess calories are consumed and heat is generated.</p>
            <p><bold>Abnormal gene product.</bold> Pathogenic variants result in decreased function which, in the beta-cell, is thought to increase ATP production and thus insulin secretion.</p>
          </sec>
        </sec>
      </sec>
      <sec id="hi.References">
        <title>References</title>
        <sec id="hi.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="hi.Literature_Cited.reflist0">
            <ref id="hi.REF.abernethy.1998.359">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abernethy</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidson</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamont</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shepherd</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunne</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <article-title>Intra-arterial calcium stimulation test in the investigation of hyperinsulinaemic hypoglycaemia.</article-title>
                <source>Arch Dis Child.</source>
                <year>1998</year>
                <volume>78</volume>
                <fpage>359</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">9623401</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.aguilarbryan.1999.101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aguilar-Bryan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryan</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Molecular biology of adenosine triphosphate-sensitive potassium channels.</article-title>
                <source>Endocr Rev.</source>
                <year>1999</year>
                <volume>20</volume>
                <fpage>101</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">10204114</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.bahibuisson.2008.945">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bahi-Buisson</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roze</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionisi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Escande</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valayannopoulos</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feillet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinrichs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chadefaux-Vekemans</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dan</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P.</given-names>
                  </name>
                </person-group>
                <article-title>Neurological aspects of hyperinsulinism-hyperammonaemia syndrome.</article-title>
                <source>Dev Med Child Neurol.</source>
                <year>2008</year>
                <volume>50</volume>
                <fpage>945</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19046187</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.barroso.2008.3161">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barroso</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wheeler</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whittaker</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wasson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeggini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weedon</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunt</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Venkatesh</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frayling</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neuman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherva</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hitman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCarthy</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattersley</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Permutt</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wareham</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deloukas</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Population-specific risk of type 2 diabetes conferred by HNF4A P2 promoter variants: a lesson for replication studies.</article-title>
                <source>Diabetes.</source>
                <year>2008</year>
                <volume>57</volume>
                <fpage>3161</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">18728231</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.beltrand.2012.198">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beltrand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caquard</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arnoux</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laborde</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Velho</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verkarre</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunelle</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nihoul-F&#x000e9;k&#x000e9;t&#x000e9;</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saudubray</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robert</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism.</article-title>
                <source>Diabetes Care.</source>
                <year>2012</year>
                <volume>35</volume>
                <fpage>198</fpage>
                <lpage>203</lpage>
                <pub-id pub-id-type="pmid">22190679</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.bonnefond.2012.e37423">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bonnefond</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Philippe</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durand</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dechaume</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huyvaert</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montagne</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marre</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balkau</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fajardy</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vambergue</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vatin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delplanque</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Guilcher</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Graeve</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lecoeur</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sand</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaxillaire</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Froguel</surname>
                    <given-names>P.</given-names>
                  </name>
                </person-group>
                <article-title>Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene.</article-title>
                <source>PLoS One.</source>
                <year>2012</year>
                <volume>7</volume>
                <fpage>e37423</fpage>
                <pub-id pub-id-type="pmid">22701567</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.burns.2008.65">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burns</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rutherford</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boardman</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowan</surname>
                    <given-names>FM</given-names>
                  </name>
                </person-group>
                <article-title>Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia.</article-title>
                <source>Pediatrics.</source>
                <year>2008</year>
                <volume>122</volume>
                <fpage>65</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">18595988</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.calabria.2012.2585">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Calabria</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Le&#x000f3;n</surname>
                    <given-names>DD</given-names>
                  </name>
                </person-group>
                <article-title>GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel.</article-title>
                <source>Diabetes.</source>
                <year>2012</year>
                <volume>61</volume>
                <fpage>2585</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">22855730</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.christesen.2002.1240">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Christesen</surname>
                    <given-names>HB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacobsen</surname>
                    <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Odili</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buettger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cuesta-Munoz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hansen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brusgaard</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Massa</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magnuson</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiota</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matschinsky</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbetti</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy.</article-title>
                <source>Diabetes.</source>
                <year>2002</year>
                <volume>51</volume>
                <fpage>1240</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11916951</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.clayton.2001.457">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eaton</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aynsley-Green</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edginton</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hussain</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krywawych</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Datta</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malingre</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Berg</surname>
                    <given-names>IE</given-names>
                  </name>
                </person-group>
                <article-title>Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion.</article-title>
                <source>J Clin Invest.</source>
                <year>2001</year>
                <volume>108</volume>
                <fpage>457</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">11489939</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.cuestamu_oz.2004.2164">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cuesta-Mu&#x000f1;oz</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huopio</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otonkoski</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomez-Zumaquero</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000e4;nt&#x000f6;-Salonen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000f3;pez-Enriquez</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Gimeno</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soriguer</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laakso</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation.</article-title>
                <source>Diabetes.</source>
                <year>2004</year>
                <volume>53</volume>
                <fpage>2164</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15277402</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.dalgaard.2011">
              <mixed-citation publication-type="other">Dalgaard LT. Genetic variance in uncoupling protein 2 in relation to obesity, type 2 diabetes, and related metabolic traits: focus on the functional -866G&#x0003e;A promoter variant (rs659366). J Obes. 2011;2011:340241.</mixed-citation>
            </ref>
            <ref id="hi.REF.damaj.2008.4941">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Damaj</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>le Lorch</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verkarre</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Werl</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hubert</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nihoul-F&#x000e9;k&#x000e9;t&#x000e9;</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aigrain</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Keyzer</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romana</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellanne-Chantelot</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaubert</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Chromosome 11p15 paternal isodisomy in focal forms of neonatal hyperinsulinism.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2008</year>
                <volume>93</volume>
                <fpage>4941</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18796520</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.de_lonlay.2001.353">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benelli</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fouque</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganguly</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aral</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionisi-Vici</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Touati</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinrichs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rabier</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamoun</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robert</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saudubray</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>Hyperinsulinism and hyperammonemia syndrome: report of twelve unrelated patients.</article-title>
                <source>Pediatr Res.</source>
                <year>2001</year>
                <volume>50</volume>
                <fpage>353</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11518822</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.de_lonlay.2002.37">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fournet</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Touati</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groos</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sevin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delagne</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayaud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chigot</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sempoux</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brusset</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laborde</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellane-Chantelot</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vassault</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Junien</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunelle</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nihoul-F&#x000e9;k&#x000e9;t&#x000e9;</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saudubray</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robert</surname>
                    <given-names>JJ</given-names>
                  </name>
                </person-group>
                <article-title>Heterogeneity of persistent hyperinsulinaemic hypoglycaemia. A series of 175 cases.</article-title>
                <source>Eur J Pediatr.</source>
                <year>2002</year>
                <volume>161</volume>
                <fpage>37</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">11808879</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.de_lonlay.2006.933">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simon-Carre</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boddaert</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giurgea</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laborde</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellann&#x000e9;-Chantelot</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verkarre</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Syrota</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seidenwurm</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nihoul-F&#x000e9;k&#x000e9;t&#x000e9;</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robert</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunelle</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaubert</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Congenital hyperinsulinism: pancreatic [18F]fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion.</article-title>
                <source>Clin Endocrinol Metab.</source>
                <year>2006</year>
                <volume>91</volume>
                <fpage>933</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">16403819</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.di_candia.2009.1019">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Candia</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gessi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pepe</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sogno Valin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mangano</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiumello</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gianolli</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proverbio</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mora</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Identification of a diffuse form of hyperinsulinemic hypoglycemia by 18-fluoro-L-3,4 dihydroxyphenylalanine positron emission tomography/CT in a patient carrying a novel mutation of the HADH gene.</article-title>
                <source>Eur J Endocrinol.</source>
                <year>2009</year>
                <volume>160</volume>
                <fpage>1019</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">19318379</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.eaton.2003.1137">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eaton</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chatziandreou</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krywawych</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hussain</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with hyperinsulinism: a novel glucose-fatty acid cycle?</article-title>
                <source>Biochem Soc Trans.</source>
                <year>2003</year>
                <volume>31</volume>
                <fpage>1137</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14641012</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.ferry.2000.239">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferry</surname>
                    <given-names>RJ</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grimberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koo-McCoy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fellows</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aguilar-Bryan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stafford</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Calcium-stimulated insulin secretion in diffuse and focal forms of congenital hyperinsulinism.</article-title>
                <source>J Pediatr.</source>
                <year>2000</year>
                <volume>137</volume>
                <fpage>239</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">10931418</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.flanagan.2009.170">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Flanagan</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clauin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellann&#x000e9;-Chantelot</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harries</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gloyn</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellard</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism.</article-title>
                <source>Hum Mutat.</source>
                <year>2009</year>
                <volume>30</volume>
                <fpage>170</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">18767144</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.flanagan.2010.987">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Flanagan</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kapoor</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mali</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cody</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwahn</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siahanidou</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banerjee</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akcay</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio-Cabezas</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shield</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hussain</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellard</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations.</article-title>
                <source>Eur J Endocrinol.</source>
                <year>2010</year>
                <volume>162</volume>
                <fpage>987</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">20164212</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.flanagan.2011.e498">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Flanagan</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patch</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Locke</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akcay</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simsek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alaei</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yekta</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desai</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kapoor</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hussain</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellard</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Genome-wide homozygosity analysis reveals HADH mutations as a common cause of diazoxide-responsive hyperinsulinemic-hypoglycemia in consanguineous pedigrees.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2011</year>
                <volume>96</volume>
                <fpage>E498</fpage>
                <lpage>502</lpage>
                <pub-id pub-id-type="pmid">21252247</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.fournet.2003.30">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fournet</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Junien</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>The genetics of neonatal hyperinsulinism.</article-title>
                <source>Horm Res.</source>
                <year>2003</year>
                <volume>59</volume>
                <supplement>Suppl 1</supplement>
                <fpage>30</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">12566718</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.glaser.2003.272">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B.</given-names>
                  </name>
                </person-group>
                <article-title>Dominant SUR1 mutation causing autosomal dominant type 2 diabetes.</article-title>
                <source>Lancet.</source>
                <year>2003</year>
                <volume>361</volume>
                <fpage>272</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">12559857</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.glaser.2011.891">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blech</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krakinovsky</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ekstein</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazor-Aronovitch</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landau</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abeliovich</surname>
                    <given-names>D.</given-names>
                  </name>
                </person-group>
                <article-title>ABCC8 mutation allele frequency in the Ashkenazi Jewish population and risk of focal hyperinsulinemic hypoglycemia.</article-title>
                <source>Genet Med.</source>
                <year>2011</year>
                <volume>13</volume>
                <fpage>891</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">21716120</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.glaser.1998.226">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kesavan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heyman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cuesta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buchs</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thornton</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Permutt</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matschinsky</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herold</surname>
                    <given-names>KC</given-names>
                  </name>
                </person-group>
                <article-title>Familial hyperinsulinism caused by an activating glucokinase mutation.</article-title>
                <source>N Engl J Med.</source>
                <year>1998</year>
                <volume>338</volume>
                <fpage>226</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">9435328</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.glaser.1999.55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landau</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Permutt</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>Neonatal hyperinsulinism.</article-title>
                <source>Trends Endocrinol Metab.</source>
                <year>1999</year>
                <volume>10</volume>
                <fpage>55</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">10322395</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.glaser.1989.71">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landau</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smilovici</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nesher</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Persistent hyperinsulinaemic hypoglycaemia of infancy: long-term treatment with the somatostatin analogue Sandostatin.</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <year>1989</year>
                <volume>31</volume>
                <fpage>71</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">2688998</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.gloyn.2001.206">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gloyn</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashim</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashcroft</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashfield</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiltshire</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>RC</given-names>
                  </name>
                  <collab>UK Prospective Diabetes Study</collab>
                </person-group>
                <article-title>(UKPDS 53). Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53).</article-title>
                <source>Diabet Med.</source>
                <year>2001</year>
                <month>Mar</month>
                <volume>18</volume>
                <fpage>206</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">11318841</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.gloyn.2004.1838">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gloyn</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pearson</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antcliff</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proks</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruining</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slingerland</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srinivasan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Molnes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edghill</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frayling</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Temple</surname>
                    <given-names>IK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackay</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shield</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sumnik</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Rhijn</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wales</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aisenberg</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nj&#x000f8;lstad</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashcroft</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattersley</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <article-title>Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.</article-title>
                <source>N Engl J Med.</source>
                <year>2004</year>
                <volume>350</volume>
                <fpage>1838</fpage>
                <lpage>49</lpage>
                <pub-id pub-id-type="pmid">15115830</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.gloyn.2005.925">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gloyn</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reimann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girard</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edghill</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proks</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pearson</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Temple</surname>
                    <given-names>IK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackay</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shield</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freedenberg</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noyes</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashcroft</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gribble</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattersley</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <article-title>Relapsing diabetes can result from moderately activating mutations in KCNJ11.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2005</year>
                <volume>14</volume>
                <fpage>925</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">15718250</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.gloyn.2003.568">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gloyn</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weedon</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Owen</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knight</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hitman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sampson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halford</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCarthy</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattersley</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frayling</surname>
                    <given-names>TM</given-names>
                  </name>
                </person-group>
                <article-title>Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes.</article-title>
                <source>Diabetes.</source>
                <year>2003</year>
                <volume>52</volume>
                <fpage>568</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">12540637</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.gong.2012.801">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gong</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tong</surname>
                    <given-names>X.</given-names>
                  </name>
                </person-group>
                <article-title>The effect of KCNJ11 polymorphism on the risk of type 2 diabetes: a global meta-analysis based on 49 case-control studies.</article-title>
                <source>DNA Cell Biol.</source>
                <year>2012</year>
                <volume>31</volume>
                <fpage>801</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">22082043</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.gonz_lezbarroso.2008.e3850">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gonz&#x000e1;lez-Barroso</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giurgea</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouillaud</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anedda</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellann&#x000e9;-Chantelot</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hubert</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Keyzer</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricquier</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in UCP2 in congenital hyperinsulinism reveal a role for regulation of insulin secretion.</article-title>
                <source>PLoS One.</source>
                <year>2008</year>
                <volume>3</volume>
                <fpage>e3850</fpage>
                <pub-id pub-id-type="pmid">19065272</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.grimberg.2001.322">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grimberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferry</surname>
                    <given-names>RJ</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koo-McCoy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polonsky</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Permutt</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aguilar-Bryan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stafford</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thornton</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baker</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations.</article-title>
                <source>Diabetes.</source>
                <year>2001</year>
                <volume>50</volume>
                <fpage>322</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11272143</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.grimberg.1999">
              <mixed-citation publication-type="confproc">Grimberg A, Ferry RJ, Kelly A, Koo-McCoy S, Glaser B, Permutt MA, Aguilar-Bryan L, Stafford D, Thornton P, Baker L, Stanley CA. Acute insulin responses (AIRS) to tolbutamide and glucose distinguish diffuse versus focal forms of congenital hyperinsulinism (HI) due to sulfonylurea receptor (SUR) mutations. Abstract. Annual Meeting of the American Endocrine Society. 1999.</mixed-citation>
            </ref>
            <ref id="hi.REF.hani.1998.1511">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hani</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boutin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durand</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Permutt</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Velho</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Froguel</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians.</article-title>
                <source>Diabetologia.</source>
                <year>1998</year>
                <volume>41</volume>
                <fpage>1511</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">9867219</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.hansen.2001.1330">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hansen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ambye</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grarup</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hansen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Echwald</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pedersen</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <article-title>Genetic variability of the SUR1 promoter in relation to beta-cell function and Type II diabetes mellitus.</article-title>
                <source>Diabetologia.</source>
                <year>2001</year>
                <volume>44</volume>
                <fpage>1330</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11692183</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.hardy.2007.765">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hardy</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hohmeier</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manduchi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doliba</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gupta</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoeckert</surname>
                    <given-names>CJ</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Matschinsky</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newgard</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaestner</surname>
                    <given-names>KH</given-names>
                  </name>
                </person-group>
                <article-title>Functional genomics of the beta-cell: short-chain 3-hydroxyacyl-coenzyme A dehydrogenase regulates insulin secretion independent of K+ currents.</article-title>
                <source>Mol Endocrinol.</source>
                <year>2007</year>
                <volume>21</volume>
                <fpage>765</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">17185391</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.hart.2002.3135">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hart</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Haeften</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dekker</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bot</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heine</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maassen</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <article-title>Variations in insulin secretion in carriers of the E23K variant in the KIR6.2 subunit of the ATP-sensitive K(+) channel in the beta-cell.</article-title>
                <source>Diabetes.</source>
                <year>2002</year>
                <volume>51</volume>
                <fpage>3135</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12351459</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.h_jlund.2004.1592">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>H&#x000f8;jlund</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hansen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lajer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henriksen</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levin</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindholm</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pedersen</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck-Nielsen</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia linked to a mutation in the human insulin receptor gene.</article-title>
                <source>Diabetes.</source>
                <year>2004</year>
                <volume>53</volume>
                <fpage>1592</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15161766</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.huopio.2002.4502">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Huopio</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>J&#x000e4;&#x000e4;skel&#x000e4;inen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komulainen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miettinen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000e4;rkk&#x000e4;inen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laakso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tapanainen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voutilainen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otonkoski</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Acute insulin response tests for the differential diagnosis of congenital hyperinsulinism.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2002</year>
                <volume>87</volume>
                <fpage>4502</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12364426</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.huopio.2003.301">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Huopio</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otonkoski</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vauhkonen</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reimann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashcroft</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laakso</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1.</article-title>
                <source>Lancet.</source>
                <year>2003</year>
                <volume>361</volume>
                <fpage>301</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12559865</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.huopio.2000.897">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Huopio</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reimann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashfield</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komulainen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenko</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vauhkonen</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kere</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laakso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashcroft</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otonkoski</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1.</article-title>
                <source>J Clin Invest.</source>
                <year>2000</year>
                <volume>106</volume>
                <fpage>897</fpage>
                <lpage>906</lpage>
                <pub-id pub-id-type="pmid">11018078</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.hussain.2004.163">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hussain</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aynsley-Green</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Medications used in the treatment of hypoglycemia due to congenital hyperinsulinism of infancy (HI).</article-title>
                <source>Pediatr Endocrinol Rev.</source>
                <year>2004</year>
                <volume>2</volume>
                <supplement>Suppl 1</supplement>
                <fpage>163</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16456495</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.inder.2008.440">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Inder</surname>
                    <given-names>T.</given-names>
                  </name>
                </person-group>
                <article-title>How low can I go? The impact of hypoglycemia on the immature brain.</article-title>
                <source>Pediatrics.</source>
                <year>2008</year>
                <volume>122</volume>
                <fpage>440</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">18676561</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.kapoor.2009.101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kapoor</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hussain</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Advances in the diagnosis and management of hyperinsulinemic hypoglycemia.</article-title>
                <source>Nat Clin Pract Endocrinol Metab.</source>
                <year>2009</year>
                <volume>5</volume>
                <fpage>101</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">19165222</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.kapoor.2008.1659">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kapoor</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Locke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colclough</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wales</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conn</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattersley</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hussain</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Persistent hyperinsulinemic hypoglycemia and maturity-onset diabetes of the young due to heterozygous HNF4A mutations.</article-title>
                <source>Diabetes.</source>
                <year>2008</year>
                <volume>57</volume>
                <fpage>1659</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">18268044</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.kassem.2000.1325">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kassem</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ariel</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thornton</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheimberg</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy.</article-title>
                <source>Diabetes.</source>
                <year>2000</year>
                <volume>49</volume>
                <fpage>1325</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">10923633</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.kassem.2010.1348">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kassem</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhandari</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodr&#x000ed;guez-Bada</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Motaghedi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heyman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Gimeno</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cobo-Vuilleumier</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maclaren</surname>
                    <given-names>NK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cuesta-Mu&#x000f1;oz</surname>
                    <given-names>AL</given-names>
                  </name>
                </person-group>
                <article-title>Large islets, beta-cell proliferation, and a glucokinase mutation.</article-title>
                <source>N Engl J Med.</source>
                <year>2010</year>
                <volume>362</volume>
                <fpage>1348</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">20375417</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.katz.1999.3117">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Katz</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferry</surname>
                    <given-names>RJ</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collett-Solberg</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baker</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Suppression of insulin oversecretion by subcutaneous recombinant human insulin-like growth factor I in children with congenital hyperinsulinism due to defective beta-cell sulfonylurea receptor.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>1999</year>
                <volume>84</volume>
                <fpage>3117</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">10487673</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.kelly.2001.3724">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ng</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferry</surname>
                    <given-names>RJ</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Grimberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koo-McCoy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thornton</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Acute insulin responses to leucine in children with the hyperinsulinism/hyperammonemia syndrome.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2001</year>
                <volume>86</volume>
                <fpage>3724</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11502802</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.kompare.2008.140">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kompare</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rizzo</surname>
                    <given-names>WB</given-names>
                  </name>
                </person-group>
                <article-title>Mitochondrial fatty-acid oxidation disorders.</article-title>
                <source>Semin Pediatr Neurol.</source>
                <year>2008</year>
                <volume>15</volume>
                <fpage>140</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18708005</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.lovegregory.2004.1134">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Love-Gregory</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wasson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ma</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jin</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suarez</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Permutt</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4 alpha gene on chromosome 20q is associated with type 2 diabetes and appears to contribute to the evidence for linkage in an ashkenazi jewish population.</article-title>
                <source>Diabetes.</source>
                <year>2004</year>
                <volume>53</volume>
                <fpage>1134</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">15047632</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.lteif.1999.619">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lteif</surname>
                    <given-names>AN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwenk</surname>
                    <given-names>WF</given-names>
                  </name>
                </person-group>
                <article-title>Hypoglycemia in infants and children.</article-title>
                <source>Endocrinol Metab Clin North Am.</source>
                <year>1999</year>
                <month>Sep</month>
                <volume>28</volume>
                <fpage>619</fpage>
                <lpage>46</lpage>
                <comment>vii.</comment>
                <pub-id pub-id-type="pmid">10500934</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.macmullen.2001.1782">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>MacMullen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsu</surname>
                    <given-names>BY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay-Debeney</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saudubray</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganguly</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Hyperinsulinism/hyperammonemia contributing investigators. Hyperinsulinism / hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2001</year>
                <volume>86</volume>
                <fpage>1782</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11297618</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.macmullen.2011.1797">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Macmullen</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snider</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tewson</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aziz</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganguly</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shyng</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Diazoxide-unresponsive congenital hyperinsulinism in children with dominant mutations of the &#x003b2;-cell sulfonylurea receptor SUR1.</article-title>
                <source>Diabetes.</source>
                <year>2011</year>
                <volume>60</volume>
                <fpage>1797</fpage>
                <lpage>804</lpage>
                <pub-id pub-id-type="pmid">21536946</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.maechler.1999.685">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Maechler</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wollheim</surname>
                    <given-names>CB</given-names>
                  </name>
                </person-group>
                <article-title>Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis.</article-title>
                <source>Nature.</source>
                <year>1999</year>
                <volume>402</volume>
                <fpage>685</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10604477</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.matschinsky.1998.307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matschinsky</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magnuson</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities.</article-title>
                <source>Diabetes.</source>
                <year>1998</year>
                <volume>47</volume>
                <fpage>307</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">9519733</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.mazoraronovitch.2007.491">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mazor-Aronovitch</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lobel</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirsch</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinhas-Hamiel</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Modan-Moses</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landau</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Long-term neurodevelopmental outcome in conservatively treated congenital hyperinsulinism.</article-title>
                <source>Eur J Endocrinol.</source>
                <year>2007</year>
                <volume>157</volume>
                <fpage>491</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17893264</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.mazoraronovitch.2009.424">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mazor-Aronovitch</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landau</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillis</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Surgical versus non-surgical treatment of congenital hyperinsulinism.</article-title>
                <source>Pediatr Endocrinol Rev.</source>
                <year>2009</year>
                <volume>6</volume>
                <fpage>424</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">19396028</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.meissner.1999.351">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meissner</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beinbrech</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E.</given-names>
                  </name>
                </person-group>
                <article-title>Congenital hyperinsulinism: molecular basis of a heterogeneous disease.</article-title>
                <source>Hum Mutat.</source>
                <year>1999</year>
                <volume>13</volume>
                <fpage>351</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">10338089</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.mohnike.2008a.65">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mohnike</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blankenstein</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minn</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohnike</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuchtner</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otonkoski</surname>
                    <given-names>T.</given-names>
                  </name>
                </person-group>
                <article-title>[18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism.</article-title>
                <source>Horm Res.</source>
                <year>2008a</year>
                <volume>70</volume>
                <fpage>65</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">18547951</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.mohnike.2008b.59">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mohnike</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blankenstein</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pfuetzner</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000f6;tzsch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schober</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steiner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardy</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grimberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Waarde</surname>
                    <given-names>WM</given-names>
                  </name>
                </person-group>
                <article-title>Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon.</article-title>
                <source>Horm Res.</source>
                <year>2008b</year>
                <volume>70</volume>
                <fpage>59</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">18493152</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.molven.2004.221">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Molven</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matre</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rishaug</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nj&#x000f8;lstad</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jellum</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>S&#x000f8;vik</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <article-title>Familial hyperinsulinemic hypoglycemia caused by a defect in the SCHAD enzyme of mitochondrial fatty acid oxidation.</article-title>
                <source>Diabetes.</source>
                <year>2004</year>
                <volume>53</volume>
                <fpage>221</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">14693719</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.morris.2012.981">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voight</surname>
                    <given-names>BF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teslovich</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreira</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Segr&#x000e8;</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinthorsdottir</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strawbridge</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khan</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grallert</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahajan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prokopenko</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kang</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dina</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esko</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraser</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanoni</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lagou</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langenberg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindgren</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller-Nurasyid</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pechlivanis</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rayner</surname>
                    <given-names>NW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiltshire</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yengo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinnunen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossin</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raychaudhuri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dimas</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loos</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vedantam</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Florez</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fox</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rybin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Couper</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kao</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cornelis</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kraft</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Dam</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stringham</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chines</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fontanillas</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmen</surname>
                    <given-names>OL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunt</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>AU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kong</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawrence</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perry</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platou</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Potter</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rehnberg</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robertson</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sivapalaratnam</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stan&#x0010d;&#x000e1;kov&#x000e1;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stirrups</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thorleifsson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tikkanen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almgren</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atalay</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benediktsson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnycastle</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burtt</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carey</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charpentier</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crenshaw</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doney</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dorkhan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edkins</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emilsson</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eury</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forsen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gertow</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gigante</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grant</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groves</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guiducci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herder</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hreidarsson</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hui</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonsson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rathmann</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klopp</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kravic</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krjut&#x00161;kov</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langford</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leander</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindholm</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lobbens</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e4;nnist&#x000f6;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mirza</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;hleisen</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Musk</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parkin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rallidis</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saramies</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sennblad</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sigur&#x000f0;sson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silveira</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinbach</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thorand</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trakalo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veglia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wennauer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winckler</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zabaneh</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Duijn</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitterlinden</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sijbrands</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abecasis</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Owen</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeggini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trip</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forouhi</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Syv&#x000e4;nen</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eriksson</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peltonen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000f6;then</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balkau</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmer</surname>
                    <given-names>CN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyssenko</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuomi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isomaa</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunter</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qi</surname>
                    <given-names>L</given-names>
                  </name>
                  <collab>Wellcome Trust Case Control Consortium</collab>
                </person-group>
                <article-title>Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; Asian Genetic Epidemiology Network&#x02013;Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium, Shuldiner AR, Roden M, Barroso I, Wilsgaard T, Beilby J, Hovingh K, Price JF, Wilson JF, Rauramaa R, Lakka TA, Lind L, Dedoussis G, Nj&#x000f8;lstad I, Pedersen NL, Khaw KT, Wareham NJ, Keinanen-Kiukaanniemi SM, Saaristo TE, Korpi-Hy&#x000f6;v&#x000e4;lti E, Saltevo J, Laakso M, Kuusisto J, Metspalu A, Collins FS, Mohlke KL, Bergman RN, Tuomilehto J, Boehm BO, Gieger C, Hveem K, Cauchi S, Froguel P, Baldassarre D, Tremoli E, Humphries SE, Saleheen D, Danesh J, Ingelsson E, Ripatti S, Salomaa V, Erbel R, J&#x000f6;ckel KH, Moebus S, Peters A, Illig T, de Faire U, Hamsten A, Morris AD, Donnelly PJ, Frayling TM, Hattersley AT, Boerwinkle E, Melander O, Kathiresan S, Nilsson PM, Deloukas P, Thorsteinsdottir U, Groop LC, Stefansson K, Hu F, Pankow JS, Dupuis J, Meigs JB, Altshuler D, Boehnke M, McCarthy MI; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes.</article-title>
                <source>Nat Genet.</source>
                <year>2012</year>
                <volume>44</volume>
                <fpage>981</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">22885922</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.nestorowicz.1998.1119">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nestorowicz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shyng</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nichols</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thornton</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Permutt</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>Genetic heterogeneity in familial hyperinsulinism.</article-title>
                <source>Hum Mol Genet.</source>
                <year>1998</year>
                <fpage>1119</fpage>
                <lpage>28</lpage>
                <pub-id pub-id-type="pmid">9618169</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.nestorowicz.1997.1743">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nestorowicz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inagaki</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonoi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoor</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landau</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thornton</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Permutt</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism.</article-title>
                <source>Diabetes.</source>
                <year>1997</year>
                <volume>46</volume>
                <fpage>1743</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9356020</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.nj_lstad.2001.1588">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nj&#x000f8;lstad</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>S&#x000f8;vik</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cuesta-Mu&#x000f1;oz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bj&#x000f8;rkhaug</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Massa</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbetti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Undlien</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiota</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magnuson</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Molven</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matschinsky</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bell</surname>
                    <given-names>GI</given-names>
                  </name>
                </person-group>
                <article-title>Neonatal diabetes mellitus due to complete glucokinase deficiency.</article-title>
                <source>N Engl J Med.</source>
                <year>2001</year>
                <volume>344</volume>
                <fpage>1588</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">11372010</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.o_al.2011.1019">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>O&#x000e7;al</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flanagan</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hacihamdio&#x0011f;lu</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berbero&#x0011f;lu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siklar</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savas Erdeve</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okulu</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akin</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atasay</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arsan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ya&#x0011f;murlu</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Clinical characteristics of recessive and dominant congenital hyperinsulinism due to mutation(s) in the ABCC8/KCNJ11 genes encoding the ATP-sensitive potasium channel in the pancreatic beta cell.</article-title>
                <source>J Pediatr Endocrinol Metab.</source>
                <year>2011</year>
                <volume>24</volume>
                <fpage>1019</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">22308858</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.otonkoski.1999.408">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Otonkoski</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amm&#x000e4;l&#x000e4;</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huopio</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cote</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cosgrove</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashfield</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komulainen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashcroft</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunne</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kere</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>PM</given-names>
                  </name>
                </person-group>
                <article-title>A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland.</article-title>
                <source>Diabetes.</source>
                <year>1999</year>
                <volume>48</volume>
                <fpage>408</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">10334322</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.otonkoski.2007.467">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Otonkoski</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiao</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaminen-Ahola</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tapia-Paez</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ullah</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parton</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuit</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quintens</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sipil&#x000e4;</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meissner</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halestrap</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rutter</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kere</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Physical exercise-induced hypoglycemia caused by failed silencing of monocarboxylate transporter 1 in pancreatic beta cells.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2007</year>
                <volume>81</volume>
                <fpage>467</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">17701893</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.otonkoski.2003.199">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Otonkoski</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaminen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ustinov</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lapatto</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meissner</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kere</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sipil&#x000e4;</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <article-title>Physical exercise-induced hyperinsulinemic hypoglycemia is an autosomal-dominant trait characterized by abnormal pyruvate-induced insulin release.</article-title>
                <source>Diabetes.</source>
                <year>2003</year>
                <volume>52</volume>
                <fpage>199</fpage>
                <lpage>204</lpage>
                <pub-id pub-id-type="pmid">12502513</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.otonkoski.2006.13">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Otonkoski</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000e4;nt&#x000f6;-Salonen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sepp&#x000e4;nen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veijola</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huopio</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hussain</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tapanainen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eskola</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parkkola</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ekstr&#x000f6;m</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guiot</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laakso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rintala</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nuutila</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minn</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography.</article-title>
                <source>Diabetes.</source>
                <year>2006</year>
                <volume>55</volume>
                <fpage>13</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16380471</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.pearson.2007.e118">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pearson</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boj</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steele</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barrett</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stals</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shield</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattersley</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <article-title>Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene.</article-title>
                <source>PLoS Med.</source>
                <year>2007</year>
                <volume>4</volume>
                <fpage>e118</fpage>
                <pub-id pub-id-type="pmid">17407387</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.pinney.2008.2877">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pinney</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacMullen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>YW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thornton</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganguly</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shyng</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations.</article-title>
                <source>J Clin Invest.</source>
                <year>2008</year>
                <volume>118</volume>
                <fpage>2877</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">18596924</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.rahier.2000.f108">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rahier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guiot</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sempoux</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Persistent hyperinsulinaemic hypoglycaemia of infancy: a heterogeneous syndrome unrelated to nesidioblastosis.</article-title>
                <source>Arch Dis Child Fetal Neonatal Ed.</source>
                <year>2000</year>
                <volume>82</volume>
                <fpage>F108</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">10685982</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.rashed.1999.183">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rashed</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahbeeni</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozand</surname>
                    <given-names>PT</given-names>
                  </name>
                </person-group>
                <article-title>Application of electrospray tandem mass spectrometry to neonatal screening.</article-title>
                <source>Semin Perinatol.</source>
                <year>1999</year>
                <fpage>183</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">10331469</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.ryan.1998.445">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ryan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devaney</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joyce</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nestorowicz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Permutt</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thornton</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <article-title>Hyperinsulinism: molecular aetiology of focal disease.</article-title>
                <source>Arch Dis Child.</source>
                <year>1998</year>
                <volume>79</volume>
                <fpage>445</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10193261</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.sagen.2008.442">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sagen</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bj&#x000f8;rkhaug</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Molnes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raeder</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grevle</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>S&#x000f8;vik</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Molven</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nj&#x000f8;lstad</surname>
                    <given-names>PR</given-names>
                  </name>
                </person-group>
                <article-title>Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry.</article-title>
                <source>Pediatr Diabetes.</source>
                <year>2008</year>
                <volume>9</volume>
                <fpage>442</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18399931</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.salopuro.2009.94">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Salopuro</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulkkinen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindstr&#x000f6;m</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kolehmainen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tolppanen</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eriksson</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valle</surname>
                    <given-names>TT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aunola</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ilanne-Parikka</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kein&#x000e4;nen-Kiukaanniemi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuomilehto</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laakso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uusitupa</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Variation in the UCP2 and UCP3 genes associates with abdominal obesity and serum lipids: the Finnish Diabetes Prevention Study.</article-title>
                <source>BMC Med Genet.</source>
                <year>2009</year>
                <volume>10</volume>
                <fpage>94</fpage>
                <pub-id pub-id-type="pmid">19769793</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.sayed.2009.1419">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sayed</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langdon</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Odili</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buettger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiffman</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suchi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taub</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grimsby</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matschinsky</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations.</article-title>
                <source>Diabetes.</source>
                <year>2009</year>
                <volume>58</volume>
                <fpage>1419</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">19336674</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.sempoux.2011.3785">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sempoux</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capito</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellann&#x000e9;-Chantelot</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verkarre</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aigrain</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fekete</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guiot</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahier</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Morphological mosaicism of the pancreatic islets: a novel anatomopathological form of persistent hyperinsulinemic hypoglycemia of infancy.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2011</year>
                <volume>96</volume>
                <fpage>3785</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">21956412</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.service.1999.1582">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Service</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Natt</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grant</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Heerden</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andrews</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorenz</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terzic</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lloyd</surname>
                    <given-names>RV</given-names>
                  </name>
                </person-group>
                <article-title>Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>1999</year>
                <volume>84</volume>
                <fpage>1582</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10323384</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.stanley.2011.465">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Two genetic forms of hyperinsulinemic hypoglycemia caused by dysregulation of glutamate dehydrogenase.</article-title>
                <source>Neurochem Int.</source>
                <year>2011</year>
                <volume>59</volume>
                <fpage>465</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">21130127</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.stanley.2000.667">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kutyna</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsu</surname>
                    <given-names>BY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ming</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poncz</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Molecular basis and characterization of the hyperinsulinism/hyperammonemia syndrome: predominance of mutations in exons 11 and 12 of the glutamate dehydrogenase gene. HI/HA Contributing Investigators.</article-title>
                <source>Diabetes.</source>
                <year>2000</year>
                <volume>49</volume>
                <fpage>667</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">10871207</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.stanley.2004.288">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thornton</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganguly</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacMullen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Underwood</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhatia</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinkrauss</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanner</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaye</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruchelli</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suchi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adzick</surname>
                    <given-names>NS</given-names>
                  </name>
                </person-group>
                <article-title>Preoperative evaluation of infants with focal or diffuse congenital hyperinsulinism by intravenous acute insulin response tests and selective pancreatic arterial calcium stimulation.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2004</year>
                <volume>89</volume>
                <fpage>288</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">14715863</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.thomas.1996.1809">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ye</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lightner</surname>
                    <given-names>E.</given-names>
                  </name>
                </person-group>
                <article-title>Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy.</article-title>
                <source>Hum Mol Genet.</source>
                <year>1996</year>
                <volume>5</volume>
                <fpage>1809</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">8923010</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.thornton.1998.9">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thornton</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Satin-Smith</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herold</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiu</surname>
                    <given-names>KC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nestorowicz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Permutt</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baker</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Familial hyperinsulinism with apparent autosomal dominant inheritance: clinical and genetic differences from the autosomal recessive variant.</article-title>
                <source>J Pediatr.</source>
                <year>1998</year>
                <volume>132</volume>
                <fpage>9</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">9469993</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.tornovsky.2004.6224">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tornovsky</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crane</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cosgrove</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hussain</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavie</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heyman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nesher</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuchinski</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben-Shushan</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shatz</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nahari</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Potikha</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zangen</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tenenbaum-Rakover</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Vries</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Argente</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gracia</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landau</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eliakim</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindley</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunne</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aguilar-Bryan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Hyperinsulinism of infancy: novel ABCC8 and KCNJ11 mutations and evidence for additional locus heterogeneity.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2004</year>
                <volume>89</volume>
                <fpage>6224</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">15579781</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.turkkahraman.2008.122">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Turkkahraman</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bircan</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tribble</surname>
                    <given-names>ND</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ak&#x000e7;urin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gloyn</surname>
                    <given-names>AL</given-names>
                  </name>
                </person-group>
                <article-title>Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy.</article-title>
                <source>J Pediatr.</source>
                <year>2008</year>
                <volume>153</volume>
                <fpage>122</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18571549</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.verkarre.1998.1286">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verkarre</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fournet</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gross-Morand</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devillers</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunelle</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robert</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nihoul-F&#x000e9;k&#x000e9;t&#x000e9;</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saudubray</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Junien</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia.</article-title>
                <source>J Clin Invest.</source>
                <year>1998</year>
                <volume>102</volume>
                <fpage>1286</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">9769320</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.won.2006.566">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Won</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tseng</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jap</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burcus</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pittenger</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vinik</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Clinical features and morphological characterization of 10 patients with noninsulinoma pancreatogenous hypoglycaemia syndrome (NIPHS).</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <year>2006</year>
                <volume>65</volume>
                <fpage>566</fpage>
                <lpage>78</lpage>
                <pub-id pub-id-type="pmid">17054456</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.yorifuji.2005.3174">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yorifuji</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagashima</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurokawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawai</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oishi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akazawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hosokawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inagaki</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakahata</surname>
                    <given-names>T.</given-names>
                  </name>
                </person-group>
                <article-title>The C42R mutation in the Kir6.2 (KCNJ11) gene as a cause of transient neonatal diabetes, childhood diabetes, or later-onset, apparently type 2 diabetes mellitus.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2005</year>
                <volume>90</volume>
                <fpage>3174</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15784703</pub-id>
              </element-citation>
            </ref>
            <ref id="hi.REF.zung.2004.5504">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zung</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaser</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nimri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zadik</surname>
                    <given-names>Z</given-names>
                  </name>
                </person-group>
                <article-title>Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2004</year>
                <volume>89</volume>
                <fpage>5504</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15531505</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="hi.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="hi.Suggested_Reading.reflist0">
            <ref id="hi.REF.ludwig.2011.45">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ludwig</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ziegenhorn</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Empting</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meissner</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marquard</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holl</surname>
                    <given-names>R</given-names>
                  </name>
                  <collab>Diabetes Patienten-Verlaufsdokumentationssystem (DPV) Group</collab>
                </person-group>
                <article-title>Mohnike K. Glucose metabolism and neurological outcome in congenital hyperinsulinism.</article-title>
                <source>Semin Pediatr Surg.</source>
                <year>2011</year>
                <volume>20</volume>
                <fpage>45</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21186004</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="hi.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="hi.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>24 January 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>15 June 2010 (cd) Revision: prenatal testing for <italic toggle="yes">HADH</italic> mutations available on a clinical basis</p>
            </list-item>
            <list-item>
              <p>23 February 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>19 August 2003 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>12 May 2003 (bg) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
